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ABSTRACT 
Objective. To report the ESICM Consensus and clinical practice recommendations on fluid therapy in 
neurointensive care patients. 
 
Design. A consensus committee including 22 international experts was conducted during ESICM 
LIVES2016 where a meeting was held for all participants in October 2016. Teleconferences and 
electronic-based discussions among the entire committee served as an integral part of the 
development of the consensus process.  
 
Methods. Population, intervention, comparison, and outcomes (PICO) questions were reviewed and 
updated as needed, and evidence profiles were generated. The consensus focused on three main 
topics: (1) general fluid resuscitation and maintenance, 2) hyperosmolar fluids for ICP control, 3) 
fluids for the management of delayed cerebral ischemia). After literature search for best available 
evidence, the principles of the Grading of Recommendations Assessment, Development, and 
Evaluation (GRADE) system were applied to assess the quality of evidence (from high to very low) and 
to formulate recommendations as strong or weak, or best practice statement when applicable. A 
modified Delphi process based on the integration of evidence provided by the literature and expert 
opinions – using a sequential approach for avoiding biases and misinterpretations – was used to 
generate final statements. 
 
Results. The panel provided 28 statements, and a total of 11 strong recommendations and 15 weak 
recommendations. No recommendations were provided for 2 questions.  
 
 
Keywords: Evidence‐based medicine – Guidelines – Fluids – Traumatic brain injury – Subarachnoid 
hemorrhage – Intracerebral hemorrhage – Stroke – Mannitol – Hypertonic – Neurointensive care. 
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INTRODUCTION 
 
Fluid therapy is a fundamental component of neurointensive care (NIC), with general indications 
(volume resuscitation and maintenance) and “neuro-specific” purposes (intracranial pressure ICP 
control, management of delayed cerebral ischemia DCI). Despite routine utilization, key questions – 
such as preferred composition, optimal volume, choice and dose of hyperosmolar fluids to control ICP 
– remain unanswered. There is no Level 1 evidence or specific recommendations to guide fluid 
therapy in NIC patients, and physiologic triggers and monitoring endpoints of fluid therapy are not 
precisely defined.  
The recommendations herein are focused primarily on providing guidance to clinicians caring for NIC 
patients and are intended to be best clinical practice but not created to represent standard of care.  
 
METHODOLOGY 
Below is a summary of important methodological considerations for the development of these 
consensus guidelines. 
 
Definitions 
We defined NIC patients as adult critically ill patients with severe traumatic brain injury (TBI), high-
grade aneurysmal subarachnoid hemorrhage (SAH), and severe stroke (ischemic AIS and 
hemorrhagic ICH). 
 
Registration 
The plan for this systematic review was registered on PROSPERO, International prospective register of 
systematic reviews, with the ID 42016052123 (http://www.crd.york.ac.uk/PROSPERO/) . 
 
Sponsorship 
No funding was provided. 
 
Conflict-of-interest policy 
No industry input into guidelines development occurred. No consensus member received honoraria 
and the process relied solely on personal disclosures.  
 
Selection of committee members 
Participants were members of the European Society of Intensive Care Medicine (ESICM), Neurocritical 
Care Society (NCS) and Latin America Brain Injury Consortium (LABIC). Chairs and co-chairs were 
appointed by the NIC section of ESICM, with an external member (DP) providing methodological 
expertise for the Grading of Recommendations Assessment, Development and Evaluation (GRADE) 
process.  
 
 
5 
 
 
Question development 
Focus was on the management of NIC patients during the intensive care phase therefore we did not 
cover fluid management in the extra-hospital setting. The guideline panel was divided into three 
sections, according to the three main questions addressed:  
 
1) General fluid management in ABI patients,  
2) Hyperosmolar fluids for ICP control and  
3) Fluid therapy for the management of DCI.  
 
Topic selection was the responsibility of the group co-chairs (GM, NS, RH) and chairs (MO, GC), with 
input from the guideline panel in each group. All guideline questions were structured in the PICO 
format (population, intervention, control, and outcomes). 
 
Search strategy, data analysis, and grading of evidence  
In the ESM, all the details of the search strategy and grading of the evidence, including advanced 
statistical approach as in meta-analyses and meta-regression, are detailed. 
 
Consensus methodology  
We used a modified Delphi process based on the integration of evidence provided by the literature 
and expert opinions. All the results of the GRADING of the evidence were available to the panel 
through a web-based file. The chairs (MO, GC) integrated the initial questions with literature revision 
and grading, and formulated 4 mutually exclusive questions and 35 questions (clustered in five 
different sections) requiring a score ranging from 1 (strongly disagree) to 10 (strongly agree). These 
questions were submitted to the members of the panel through a web-based system. For each 
question or cluster of questions the experts could provide comments to integrate their answers. The 
answers were analysed by a non-voting member of the panel (DP). Answers providing scores were 
analysed as medians, 20th, and 80th percentiles. Further, scores were clustered into low (1-3), 
intermediate (4-7), and high (8-10), and analysed with correspondence analysis. Both approaches 
were used to spot answers that provided clear-cut positions among experts, particularly those 
polarized on agreement or disagreement. Correspondence analysis was used to assess if single 
members of the panel provided specific response patterns, especially when intermediate positions 
were taken. The results of the analyses were returned to the panel anonymously. The same list of 
question was then submitted to the panel in a second round. 
On the basis of the analysis of the second round of questions, statements were formulated by the 
chairs (MO, GC) selecting questions with higher degrees of agreement, and then submitted to the 
panel. Answers were analysed with correspondence analysis to spot heterogeneity among the panel 
members. Single panel members, who presented heterogeneous answer patterns, were provided 
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feedbacks on their answers with request to confirm their vote, thereby allowing the detection of 
misinterpretations of some statements.  
A final vote was required for confirmation, with >80% of voting members necessary for a strong 
recommendation (for or against). When votes for or against (a mix of strong and weak options) didn’t 
reach the 80% threshold, then a weak recommendation was provided. In case of minor concerns 
panel members could declare reservation. In case of major concerns a stand aside position was 
adopted, no blocking option was permitted, and reasons for concerns were reported. 
 
RESULTS 
 
1. FLUIDS FOR THE GENERAL MANAGEMENT OF ABI PATIENTS 
1.1. Analysis of available evidence 
Question 1:  Is there evidence on efficacy and safety of albumin compared to crystalloids?  
One multicenter RCT in AIS patients found comparable 90-day outcome of 25% albumin (n=422) vs. 
normal saline (NS) (n=419), administered within 5 hours from ictus [19]. One single-center 
observational study (n=82) in AIS patients found that high-dose albumin was associated with better 
outcome (OR 1.81 95% CI 1.11-2.94) [21]. These two studies were considered sufficiently 
homogeneous to contribute to the same body of evidence. GRADE: high quality evidence (against). 
The following studies, instead, were too heterogeneous to be combined in an overall body of 
evidence. Their individual grading (reported in the ESM), hence corresponds to the body of evidence 
grading. 
A subgroup analysis performed on TBI patients from the multicenter SAFE trial found higher 2-year 
mortality (33.2 vs. 20.4%) of 4% albumin (n=214) vs. NS (n=206) [20]: excess mortality was strikingly 
higher in severe TBI (41.8 vs. 22.2%; RR 1.88 95% CI 1.31-2.70) vs. no significant difference in 
moderate TBI patients. GRADE: low quality evidence (in favour). 
Two additional studies were analyzed. One multicenter propensity score adjusted study (n=5400) [22] 
and one retrospective single-center study (n=42) [23] in SAH patients found that albumin use was 
associated with better outcomes. GRADE: very low quality evidence (in favour). 
 
Question 2: Is there evidence on efficacy and safety of synthetic colloids compared to crystalloids?  
Studies were too heterogeneous to be combined in an overall body of evidence. Their individual 
grading hence corresponds to the body of evidence grading. 
One single-center propensity score matching study (n=123) in SAH patients found that colloids 
(plasma, dextran, starch and/or albumin amongst 41 patients) were associated with significantly 
worse NIHSS scale [24]. GRADE: low quality evidence (against). 
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Two additional studies were analyzed. One study, examining data from SAH patients recruited from 
two RCTs (n=160) found that the cumulative daily colloid dose (4% gelatin or 6% penta-starch) was 
associated with worse 6-month Glasgow Outcome Score (GOS: adjusted OR 2.53 95% CI 1.13-5.68), 
while crystalloids (L/day) promoted favorable recovery (adjusted OR 0.27 95% CI 0.11-0.67) [25] 
GRADE: very low quality evidence (in favour). 
In severe TBI patients, Cox proportional hazard modeling of single-center data (n=171) found no 
association between cumulative penta-starch dose and mortality [26]. GRADE: very low quality 
evidence (against). 
 
Question 3: Is there evidence on efficacy and safety of balanced crystalloid solutions compared to 
standard crystalloids?  
No studies considered robust outcomes as survival and good neurological recovery. 
Two small single-center RCTs, one in SAH patients (n=36) [27] and another one in TBI patients (n=41) 
[28] found that, compared to NS, balanced solutions reduced the rate of hyperchloremia (a secondary 
outcome in our revision design). Despite the body of evidence was considered low (high degree of 
imprecision due to the small sample size and the risk of inflated effect [29]), a protective, although 
quantitatively small, effect of balanced solutions appears highly plausible. The studies had a 
sufficiently homogenous design to allow a meta-analysis (Figure in ESM). GRADE: low quality 
evidence (in favour).  
In addition, one RCT in TBI patients (n=34, two centers) found that Ringer-lactate significantly reduced 
serum sodium and osmolarity compared to hypertonic saline, however average serum sodium and 
osmolarity (148 mEq/L and 320 mOsm/L, respectively) were never into the high range with the use of 
both fluids [30]. GRADE: very low-quality evidence (in favour). 
 
Question 4: Is there evidence on efficacy and safety of infusions of hypertonic fluids compared to 
isotonic fluids, given as resuscitation solutions?  
Studies were too heterogeneous to be combined in an overall body of evidence. Their individual 
grading hence corresponds to the body of evidence grading. Importantly, all studies were performed 
in TBI patients. 
One RCT comparing a bolus infusion (250 mL) of 7.5% HTS to RL (n=113 patients in each group) given 
in the pre-hospital setting reported no differences in 6-month mortality and GOS [31]. GRADE: high 
quality evidence (against). 
Baker et al. in a RCT (n=64) compared 7.5% HTS/6% dextran solutions to NS (given as a single 250 mL 
resuscitation dose) and found no significant difference in 30-day mortality and GOS [32]. GRADE: low 
quality evidence (against). 
Shackford et al. in a RCT (n=34, two centers) comparing 1.6% HTS to RL for resuscitation purposes 
reported no significant difference in GOS at hospital discharge [30]. GRADE: very low quality 
evidence (against).  
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1.2 FLUIDS FOR THE GENERAL MANAGEMENT OF ABI PATIENTS: RECOMMENDATIONS. 
A total of 20 recommendations (8 strong and 12 weak recommendations) could be formulated. All are 
summarized in Table 1. 
 
2. HYPEROSMOLAR FLUIDS FOR THE MANAGEMENT OF ELEVATED ICP  
2.1. Analysis of the available evidence 
 
Question 1: Are available hyperosmolar fluids effective in reducing ICP?  
 
RCT’s 
We found one comparative RCT (60 patients, 2 centers) in severe TBI patients showing that 
hypertonic lactate, administered as a continuous prophylactic infusion over the first 48 hours from 
ICU admission, was more effective than NS in preventing episodes of elevated ICP (>20 mmHg) (% ICP 
reduction 30% 95% CI -50.4 to -4.8 %; NNTB 3 95% CI 2-21) [33].  
 
Observational studies 
Despite limitations (limited sample size, no adjustments for confounders), a high number of before-
after studies investigating the effectiveness of mannitol (MAN) and hypertonic saline (HTS) in 
reducing ICP across a spectrum of different acute brain conditions were available [34-60], allowing to 
perform specific meta-analysis to examine whether a common trend could be determined. The 
dedicated PubMed search code, the studies selection criteria, and the methodology used for meta-
analysis and meta-regression are extensively reported in the ESM. 
The flow chart of selection for inclusion of MAN and HTS studies in meta-analyses and meta-
regressions is summarized in Figure in ESM.  
 
Mannitol 
Meta-analysis revealed that MAN resulted in an 11.4 mm Hg reduction in ICP (95%-CI 8.3-14.5 mm 
Hg, p < 0.001, Figure 1). Heterogeneity was statistically significant (I2=69%; 95%-CI 38-88%, p < 0.001). 
The sensitivity analysis using high correlation between before and after measurements was consistent 
with these findings (ESM fig).  
By meta-regression, for every 1 mm Hg increase in baseline ICP, MAN bolus yielded an extra 0.55 mm 
Hg ICP reduction (p < 0.001, Figure 2); the heterogeneity estimate dropped to 0% (p = 0.573). 
However, the degree of imprecision was high and this finding should be interpreted with prudence. 
The meta-regression assuming high correlation provided similar results, but heterogeneity was highly 
significant (p < 0.001), (fig ESM).  
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Using funnel plots, asymmetry was found to be statistically significant in the meta-analysis (p = 0.005, 
Figure in ESM) and improved strikingly with the meta-regression (p = 0.897, Figure in ESM), a result 
confirmed by the sensitivity analysis. 
Mannitol dose 
By meta-regression, the extent of ICP reduction did not correlate with MAN dose (0.2638 mm Hg per 
100 mg, p = 0.711). However, by multivariable analysis after adjusting for initial ICP, the relationship 
of MAN dose with ICP was close to statistical significance in the main analysis (p = 0.065, Table 1) and 
was statistically significant in the less conservative sensitivity analysis (p = 0.0193, Table ESM). 
Obviously, heterogeneity p values had an opposite behaviour, with absence of statistical significance 
in the main analysis and highly significant heterogeneity in the sensitivity analysis. The results of this 
analysis should be treated with the greatest of caution because an insufficient number of studies 
were included in the model. 
 
 
 
Hypertonic saline. 
Hypertonic saline resulted in an average 8.8 mm Hg ICP reduction (95%-CI 6.5-11.1 mm Hg, p < 0.001, 
Figure 3). Heterogeneity was high (I2=77%, 95%-CI 45-94, p < 0.001). The meta-regression using 
baseline ICP with post-HTS ICP reduction produced a statistically significant result (slope 0.343, p = 
0.040), despite heterogeneity (CI 0-91%, Figure 4) and two studies with Cook distances of 3.4 and 1.8 
that strongly influenced the slope. 
In summary, there is enough evidence to conclude that MAN and HTS are both effective in reducing 
ICP. GRADE: low quality evidence (in favour). 
 
Question 2: Is there any evidence that hyperosmolar fluids have different efficacy (more or less 
effective) in reducing ICP?  
Studies were too heterogeneous to be combined in an overall body of evidence. Their individual 
grading hence corresponds to the body of evidence grading. Heterogeneity in study design, mainly 
treatment protocols, did not allow us to perform a meta-analysis. Results were also heterogeneous 
and are reported in detail in the ESM. 
Nine RCTs were found, comparing different hyperosmolar fluids administered as infusion boluses to 
treat elevated ICP: six studies were performed in TBI patients [35, 38, 61-64], two studies with an 
heterogeneous population of TBI and SAH patients [65, 66] and one study with AIS patients [57]. Eight 
studies compared MAN to HTS [35, 38, 57, 62], and one study compared MAN to HTL [61]. Evidence 
from all these RCTs (besides one [57]) was equally rated. GRADE: low quality evidence (in favour or 
against according to specific study findings). 
One observational study comparing hypertonic drugs was found [67]. 
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RCTs comparing hypertonic fluids given in equiosmolar doses (7 studies, N=186 patients) 
One study (n=9 in a crossover design, single-centre) found that 7.5% HTS/6% dextran vs. 20% MAN 
yielded a greater ICP reduction at 60 min (-5 mmHg 95%-CI -10.8 to – 3], p 0.014) [65], while four 
other studies (n=20 [38], n=47 [35], n=38 [62], n=29 [63]) found that 7.5%, 3%, 15% HTS and 20% 
MAN were equally effective in reducing ICP. One study (n=9) investigating ICP reduction using 7.5% 
HTS/6% dextran and 20% MAN, did not compare the two groups with formal statistical tests and 
received a very low evidence grading [57]. 
Ichaï et al. (n=34, single-centre) found that half-molar hypertonic lactate was more effective than 20% 
MAN in reducing elevated ICP, however the difference in ICP decrease at 4 hours in favour of 
hypertonic lactate (2.7 mmHg), although statistically significant, was of limited clinical relevance [61].  
 
RCTs comparing hypertonic fluids given in non equiosmolar doses (2 studies, n=52 patients)  
In these studies, HTS osmotic charge was higher than that of MAN, therefore favouring HTS. Vialet et 
al. (n=20, single-centre) found that 7.5% HTS was more effective than half the osmotic dose of 20% 
MAN in reducing the daily number of episodes with elevated ICP <25 mmHg (6 vs. 13) [64]. A second 
study (n=32) found a statistically significant ICP percentage reduction with HTS/HES 200/0.5 
compared to 15% MAN,[66]. 
 
Observational studies comparing hypertonic fluids 
We found an additional multicentre observational study that reported superiority of 3% HTS over 20% 
MAN in reducing ICP. Evidence provided by this study was rated as very low quality (in favour) [67]. 
 
Question 3: Is there evidence supporting the use of hyperosmolar fluids without ICP monitoring?  
One RCT performed on ICH patients (n=24) found that MAN and HTS had comparable effects on shift 
reduction as measured by MRI [68]. A second RCT in severe AIS patients (n=9) found that MAN and 
HTS had comparable effects on CBF increase measured by PET [69]. GRADE: very low-quality 
evidence. 
Several observational studies investigated the effects of hyperosmolar fluids (MAN or HTS) in patients 
in whom monitoring consisted of trans-cranial Doppler [41, 59, 70], positron emission tomography 
[36, 55], Xenon-CT [59, 71, 72], CT scan (to measure brain volume and shift, water content) [44, 73-
76] or EEG [77]. GRADE: very low-quality evidence. 
 
Question 4: Is there evidence that hyperosmolar fluids used improve outcome?  
 
Randomized controlled trials 
The RCTs were heterogeneous and could not be combined in a meta-analysis. Their individual grading 
hence corresponds to the body of evidence grading.  
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One multicentre RCT performed in TBI patients (n=226) found that pre-hospital resuscitation with HTS 
vs. NS did not change 6-month GOS-E [31].GRADE: high quality evidence.  
One RCT performed on TBI patients (n=60; two centers) and found that prophylactic half-molar 
hypertonic lactate although significantly reducing the number of episodes of ICPO increase over 20 
mmHg it did not improve 6-month outcome compared to NS [33]. In a previous study in TBI patients, 
hypertonic lactate, given to treat elevated ICP, was associated with better 12-month outcome 
compared to MAN (69 vs. 35%), a barely non significant results (p 0.084) [61]  
In another RCT in TBI patients, there was no mortality difference between 20% MAN and 7.5% HTS 
used to treat elevated ICP>15 mmHg [35]. 
The three RCTs were equally downgraded for methodological limitations. GRADE: low quality 
evidence (in favour or against according to the study findings).  
 
Observational studies 
One study using a propensity-score matched design applied to data from ICH patients included in the 
INTERACT-2 trial found no significant outcome difference between MAN-treated (n=1533) and non-
MAN treated (n=993) group [78]. GRADE: low quality evidence.  
One study reported that MAN may negatively affect AIS patients outcomes [79], while in another 
study HTS/dextran improved survival of TBI patients with hypotension [80]. GRADE: very low quality 
evidence.  
 
2.2 HYPEROSMOLAR FLUIDS FOR THE MANAGEMENT OF ELEVATED ICP: RECOMMENDATIONS. 
A total of 9 recommendations (2 strong recommendations, 7 weak recommendations) could be 
formulated (see Table 1). 
 
3. FLUIDS FOR THE MANAGEMENT OF CEREBRAL ISCHEMIA 
3.1. Analysis of the available evidence 
Question 1: Is there evidence to prefer specific fluids (crystalloids/colloids) in the prevention of DCI 
(CBF or clinical) in SAH patients?  
Studies were too heterogeneous to be combined in an overall body of evidence. Their individual 
grading hence corresponds to the body of evidence grading. We considered studies focused on the 
prevention of new secondary cerebral ischemic events, i.e. vasospasm and DCI and its consequences, 
in SAH patients. We report separately RCTs and observational studies. 
 
Randomized controlled trials.  
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Compared to normovolemia (2L/day crystalloids), triple H therapy (4 L/day hypervolemic 
hypertensive haemodilution fluid therapy, including colloids and crystalloids) did not change the 
proportion of patients with vasospasm signs on TCD, regional CBF, and 1-year GOS (n=32 patients, 2 
centres) [81]. Lennihan et al. (n=82 patients, single-centre) similarly found no improvement of 
regional and global CBF, or differences in the rate of vasospasm and cerebral infarction between 
prophylactic hypervolemic therapy (including colloids and crystalloids) and normovolemic therapy 
[82]. GRADE: very low-quality evidence (against). A third RCT was not included in our analysis 
because it combined multiple interventions (including volume expansion) for the prevention of 
vasospasm, thus not providing reliable information of single elements of the therapeutic approach 
[83].  
 
Observational studies. 
We included 13 observational studies, all single-centre, including small sample sizes and having 
heterogeneous treatment protocols and outcomes. It was therefore not possible to combine them in 
a single body of evidence. We made a detailed reporting of our grading process only for six studies 
using statistical techniques to adjust for confounding factors: several studies found that higher fluid 
volumes and positive fluid balance were associated with worse morbidity and neurological outcomes 
[22, 84, 85] (see also chapter 1). 
When examining studies specifically addressing the DCI phase, Ibrahim et al., using a propensity-score 
matched analysis on 123 patients found that the administration of colloids and a positive fluid 
balance were associated with significantly worse outcomes [24]. 
Another study (n=288 patients), also specifically addressing DCI and adjusting for confounders with 
propensity scores, found that positive fluid balance was associated with poor functional outcome 
[86]. Among studies not performing statistical adjustment for confounders, six examined the effect of 
fluid therapy on CBF and CBF surrogates. Hypervolemia (using colloids and crystalloids) modestly 
increased regional CBF but without improving PbtO2 [87]. Volume expansion with HTS was associated 
with an improvement of PbtO2 and CBF [71, 88, 89]. In contrast, volume expansion with albumin was 
associated with a CBF decrease [90], while NS had no effect on CBF [91].  
All the studies were equally downgraded. GRADE: very low quality evidence (in favour or against 
according to the study findings).  
 
Question 2: Does fluid therapy in the management of DCI influence outcome?  
Studies were too heterogeneous to be combined in an overall body of evidence. Their individual 
grading hence corresponds to the body of evidence grading.  
 
A multicenter RCT AIS patients (n=1267) found that haemodilution (by venisection followed by 
dextran replacement) vs. standard treatment did not change 6-month outcome [92]. GRADE: 
moderate quality evidence (against). 
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In AIS patients (N=193) daily fluid intake > 1650 ml was associated with malignant brain oedema (OR 
13.86 95 % CI 5.11–37.60) [93]. GRADE: very low quality evidence (against). 
Additional observational studies (not performing any statistical adjustment for confounders, using 
small sample size and heterogeneous design to be assessed with a meta-analytical approach) are 
listed below for, at best, hypotheses-generating purposes: 
- CBF: In patients with SAH and vasospasm, boluses of NS (n=6) [94] or HTS (n=35) [59] 
significantly improved CBF, whilst hypervolemia (albumin, dextran, and 10% glycerol) normalized 
CBF in the cerebral hemisphere where perfusion was reduced by vasospasm [95]. In contrast, 
volume expansion with colloids and albumin [96] and isovolemic hemodilution obtained by 
venisection and infusion of albumin and dextran [97] did not increase CBF. 
- Clinical endpoints: Two studies found that hypervolemia (albumin, glycerol, dextran, or plasma) 
targeted to hemodynamic monitoring (Swan-Ganz catheter) [98, 99] led to neurologic 
improvement and absence of progression to infarction in most patients. Several limitations 
(small sample size, absence of an instrumental diagnosis of vasospasm, no specific definition of 
teatment, and lack of adjustment for confounding factors) preclude any definitive conclusion. 
 
Question 3: Is there enough evidence to prefer specific fluids (crystalloids/colloids) in the management 
of cerebral ischemia for CBF augmentation/clinical outcome?  
One observational study (n=160 patients) found that colloid dose (L/day) was associated with 
unfavourable 6-month GOS (OR 2.53 95% CI 1.13-5.68), while at the contrary crystalloids were 
associated with a reduced likelihood of unfavourable outcome (OR 0.27 95% CI 0.11-0.67) [25].  
GRADE: very low quality evidence (against).  
 
Question 4: Is brain monitoring useful as a trigger or endpoint to guide fluid therapy in the 
management of DCI?  
One study on SAH patients (n=10) found that albumin (250 mL fluid bolus) increased cardiac index an 
improve PbtO2 [100], however the limited sample size, despite using multivariable approach to 
account for multiple measurements, raises internal and external validity issues. GRADE: very low 
quality evidence (in favour).  
 
Question 5: Should a change in neurological status trigger a modification in fluid management away 
from normovolemia in patients with cerebral ischemia?  
Studies were too heterogeneous to be combined in an overall body of evidence. Their individual 
grading hence corresponds to the body of evidence grading.  
Two studies treated new neurological symptoms in SAH patients with hypervolemia (albumin, 
glycerol, dextran, or plasma). A subset of patients were monitored with Swan-Ganz catheter: 
neurologic improvement and absence of progression to infarction in most cases led the authors to 
conclude that hypervolemic therapy was effective [98, 99]. The two studies, however, had very 
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serious limitations connected to the small sample size, to the absence of a instrumental diagnosis of 
vasospasm, no specific definition of teatment, and lack of adjustment for confounding factor. GRADE 
for both studies: very low quality evidence (in favour). 
 
Question 6: Is there a place for early-goal directed fluid therapy in the management of DCI? 
One RCT in SAH patients (n=160), comparing fluid management targeted to keep high global end-
diastolic volume index (GEDI, measured by trans-pulmonary thermodilution) vs. standard 
management found no effect on DCI and 3 moths poor outcome frequency [101]. A predefined 
analysis on high-grade SAH patients that were stratified at randomization, showed a statistically 
significant reduction of both outcomes. However, according to our calculation that used the same 
statistical tests as the authors neither result was statistically significant (p=0.10 for DCI and p=0.07 for 
3-month poor outcome). GRADE: moderate quality evidence (against). 
Three observational studies, using logistic regression models, found that trans-pulmonary 
thermodilution (with the use of Cardiac Function Index [102] and GEDI [103, 104]) was associated 
with better outcomes. GRADE: very low quality evidence (in favour). 
 
3.2 FLUIDS FOR THE MANAGEMENT OF CEREBRAL ISCHEMIA: RECOMMENDATIONS. 
Two recommendations (1 strong recommendation, 1 weak recommendation) could be formulated 
(see Table 1). 
 
A summary of all RCT’s on fluid therapy in NIC patients is given in Table 2.  
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Table 1: Summary of recommendations (see methods for details). Strong recommendation (for or 
against) >80% of voting members. When votes for or against (a mix of strong and weak options) didn’t 
reach the 80% threshold, then a weak recommendation was provided. In case of minor concerns 
panel members could declare reservation. In case of major concerns a stand aside position was 
adopted. 
 RECOMMENDATIONS 
FLUIDS FOR THE GENERAL 
MANAGEMENT OF ABI 
PATIENTS 
1. We recommend the use of crystalloids as preferred 
maintenance fluids in ABI patients (Strong recommendation). 
2. We do not recommend the use of colloids, hypotonic 
solutions, glucose-containing hypotonic solutions, or albumin 
as maintenance fluids in ABI patients (Strong 
recommendation). 
3. We do not recommend using high-dose albumin solutions in 
AIS patients (Strong recommendation). 
4. We suggest using crystalloids as first-line resuscitation fluids 
in ABI patients with low blood pressure (Weak 
recommendation). 
5. We suggest that synthetic colloids should not be used as 
resuscitation fluids in ABI patients with low blood pressure 
(Weak recommendation). 
6. We do not recommend using hypotonic solutions and 
glucose-containing hypotonic solutions as resuscitation fluids 
in ABI patients with low blood pressure (Strong 
recommendation). 
7. We suggest that 4% albumin solution should not be used as 
resuscitation fluid in ABI patients with low blood pressure 
(Weak recommendation). 
8. We suggest that 20% albumin should not be used as 
resuscitation fluid in ABI patients with low blood pressure 
(Weak recommendation). 
9. We suggest that hypertonic saline solutions should not be 
used as resuscitation fluids in ABI patients with low blood 
pressure (Weak recommendation). 
10. We suggest that clinicians consider targeting normovolemia 
during fluid replacement in ABI patients (Weak 
recommendation). 
11. We recommend that a multimodal approach, guided by the 
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integration of more than a single hemodynamic variable, is 
used to optimize fluid therapy in ABI patients (Strong 
recommendation).  
12. We recommend that clinicians consider using arterial blood 
pressure and fluid balance as the main endpoints to optimize 
fluid therapy in ABI patients (Strong recommendation). 
13. We suggest that clinicians integrate other variables (such as 
cardiac output, SvO2, blood lactate, urinary output) to 
optimize fluid therapy in ABI patients (Weak 
recommendation). 
14. We do not recommend central venous pressure (CVP) alone 
as an endpoint for guiding fluid therapy in ABI patients 
(Strong recommendation). 
15. We do not recommend using restrictive fluid strategies 
(aiming for an overall negative fluid balance) in ABI patients 
(Weak Recommendation). 
16. We suggest using fluid balance as a safety endpoint for fluid 
therapy in ABI patients (Weak recommendation). 
17. We suggest monitoring electrolytes (Na+, Cl-) as a safety 
endpoint for fluid therapy in ABI patients (Weak 
recommendation). 
18. We suggest monitoring osmolarity as a safety endpoint for 
fluid therapy in ABI patients (Weak recommendation). 
19. We suggest that, when available, ICP should be used as a 
safety endpoint for fluid therapy in ABI patients (Weak 
recommendation). 
20. We do not recommend using CVP monitoring as safety 
endpoint for fluid therapy in ABI patients (Strong 
recommendation). 
HYPEROSMOLAR FLUIDS FOR 
THE MANAGEMENT OF 
ELEVATED ICP 
1. We suggest that either MAN or HTS solutions can be used for 
reducing increased ICP (Weak recommendation) 
2. We do not know whether hypertonic lactate solutions should 
be recommended as a first-line osmotic solutions for 
reducing increased ICP (No recommendation) 
3. We suggest that clinicians consider using a pre-defined 
trigger for starting osmotherapy to treat elevated ICP (Weak 
recommendation) 
4. We recommend that clinicians use a combination of clinical 
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and neuromonitoring variables for starting osmotherapy to 
treat elevated ICP (Strong recommendation) 
5. We recommend a combination of neurological worsening 
(defined as a decrease of 2 points of the GCS motor score, or 
loss of pupillary reactivity or asymmetry, or deterioration of 
head CT findings) and ICP > 25 mmHg as a trigger for starting 
osmotherapy to treat elevated ICP (Strong recommendation). 
6. We suggest using an ICP threshold > 25 mmHg independent 
of other variables as a trigger for starting osmotherapy to 
reduce ICP (Weak recommendation). 
7. We are uncertain whether an ICP threshold 20-22 mmHg 
independent of other variables should be used as a trigger for 
starting osmotherapy to reduce ICP (No recommendation).  
8. We do not recommend using an ICP threshold of 15 mmHg 
independent of other variables as a trigger for starting 
osmotherapy to reduce ICP (Strong recommendation). 
9. We suggest monitoring serum osmolarity and electrolytes to 
limit the side effects of osmotherapy (Weak 
recommendation).  
10. We suggest monitoring ICP response to hyperosmolar fluids 
to limit the side effects of osmotherapy (Weak 
recommendation). 
11. We suggest monitoring the effects of hyperosmolar fluids on 
arterial blood pressure and fluid balance as secondary 
variables to limit the side effects of osmotherapy (Weak 
recommendation). 
FLUIDS FOR THE MANAGEMENT 
OF CEREBRAL ISCHEMIA 
1. We recommend assessing the efficacy of fluid infusion in SAH 
patients with DCI using a multimodal approach that includes 
arterial blood pressure and reversal of neurological deficit as 
the main endpoints (Strong recommendation). 
2. We suggest considering reduction of TCD flow velocities, 
improvements of cerebral perfusion and reduction of mean 
transit time on CT perfusion as secondary endpoints in 
assessing the efficacy of fluids for reversal of DCI in SAH 
patients (Weak recommendation). 
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Table 2. Summary of randomized controlled trials on fluid therapy in 
neurointensive care patients. 
 
Reference Population Patient nr Intervention Control Outcomes 
 
Fluids for the general management (resuscitation and maintenance) 
Ginsberg, 2013  AIS N=841 25% albumin N-Saline Comparable 3-months mRS score 
 
Myburgh, 2007 TBI N=420 4% albumin N-Saline 4% albumin group had higher mortality (33.2 
vs. 20.4% in N-Saline group) 
 
Lehmann, 2013 SAH N=36 Balanced crystalloids/colloids N-Saline/HES Balanced solutions Reduced the rate of 
hyperchloremia 
 
Roquilly, 2013 TBI N=41 Balanced crystalloids/HES N-Saline/HES Balanced solutions reduced the rate of 
hyperchloremia 
 
Shackford, 1998 TBI N=34 1.6% HTS R-Lactate Comparable GOS at hospital discharge 
 
Cooper, 2004 TBI N=226 7.5% HTS R-Lactate Comparable 6-months mortality and GOS-E 
 
Baker, 2009 TBI N=64 7.5% HTS/6% dextran N-Saline Comparable 1-month mortality and GOS 
      
Hyperosmolar fluids for the management of elevated ICP 
Ichaï, 2013 TBI N=60 1/2-molar H-Lactate N-Saline H-Lactate vs. N-Saline had greater efficacy 
in preventing ICP elevations and improved 
6-months GOS (60 vs. 50%) 
 
Battison, 2005 TBI+SAH N=18 7.5% HTS/6% dextran 20% MAN HTS vs. MAN yielded a greater ICP 
reduction 
 
Francony, 2008 TBI N=20 7.5% HTS 20% MAN Comparable effectiveness in reducing ICP 
 
Cottenceau, 2011 TBI N=47 7.5% HTS 20% MAN Comparable effectiveness in reducing ICP 
and mortality 
 
Ichaï, 2009 TBI N=34 1/2-molar H-Lactate 20% MAN H-Lactate vs. MAN was more effective in 
reducing elevated ICP improved 1-year 
GOS (69 vs. 35%) 
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Vialet, 2003 TBI N=20 7.5% HTS 20% MAN HTS vs. MAN was more effective in 
reducing elevated ICP 
 
Harutjunyan, 2004 TBI+SAH N=32 7.2% HTS/HES 200/0.5 15% MAN Comparable effectiveness in reducing ICP 
 
Jagannatha, 2016 TBI N=38 3% HTS 20% MAN Comparable effectiveness in reducing ICP 
 
Sakellaridis, 2011 TBI N=29 15% HTS 20% MAN Comparable effectiveness in reducing ICP 
 
Schwarz, 1998 AIS N=9 7.5% HTS/6% dextran 20% MAN Comparable effectiveness in reducing ICP 
 
Misra, 2007 ICH N=24 20% MAN N-Saline Comparable effectiveness in reducing MRI-
measured brain shift  
 
Diringer, 2011 AIS N=9 23.4% HTS 20% MAN Comparable effectiveness in increasing CBF 
      
Fluids for the management of cerebral ischemia 
Egge, 2001 SAH N=32 Triple H therapy  
(4L crystalloids/colloids) 
Normovolemia  
(2L crystalloids) 
Comparable regional CBF, and rate of 
vasospasm and 1-year GOS 
 
 
Lennihan, 2000 SAH N=82 Triple H therapy 
(crystalloids/colloids) 
Normovolemia 
(crystalloids/colloids) 
Comparable regional and global CBF, and 
rate of vasospasm and cerebral infarcts 
 
 
Italian Acute 
Stroke Study 
Group, 1988 
AIS N=1267 Haemodilution 
(venisection/dextran 
replacement) 
N-Saline Comparable proportion of dead and severely 
disabled patients at 6 months 
 
 
Mutoh, 2014 SAH N=160 Fluid therapy targeted to 
transpulmonary thermodilution 
Standard management Comparable rate of delayed cerebral 
ischemia and 3-months mRS scores 0-3 
 
 
Abbreviations: AIS, acute ischemic stroke; CBF, cerebral blood flow; GOS, Glasgow 
Outcome Score; HES, hydroxyl-ethyl starch; H-lactate, hypertonic sodium lactate, HTS, 
hypertonic saline; ICH, intracerebral hemorrhage; ICP, intracranial pressure; MAN, 
mannitol; mRS, modified Rankin Scale; N-Saline, normal saline; SAH, subarachnoid 
hemorrhage; TBI, traumatic brain injury 
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Figure 1. Meta-analysis examining the efficacy of mannitol in reducing ICP. 
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Figure 2. Meta-regression showing the magnitude of mannitol effect on ICP reduction, according to 
initial pre-treatment ICP. 
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Figure 3. Meta-analysis examining the efficacy of hypertonic saline in reducing ICP. 
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Figure 4. Meta-regression showing the magnitude of hypertonic saline effect on ICP reduction, 
according to initial pre-treatment ICP. 
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Search strategy 
 
Consistently with the three research topics we searched the MEDLINE database for studies 
concerning NIC patients and fluid therapy. At least two members of each study group screened the 
titles, the abstracts, and retrieved the full-texts, and the methodologist (DP) selected the articles that 
met the inclusion criteria.  Data extraction was performed according to a predefined plan, using 
dedicated electronic forms.  
We presented categorical variables as event rates in treatment arms and controls, absolute risks, 
absolute risk reductions, and relative risks.  We reported multivariate analysis results as adjusted odds 
(OR) or hazard ratios (HR). Numbers needed to treat (NNT) were calculated when appropriate. We 
calculated confidence intervals (CI) for all the above measures. CI for the NNT include the area of 
numbers to treat for benefit (NNTB) and the area of NNT to be harmed (NNTH), separated by an 
infinity value which corresponds to an absolute risk difference of zero. Continuous variables were 
reported as means or medians, standard deviation (SD) or interquartile ranges (IQR).  We represented 
absolute and relative risks from randomized controlled trials (RCTs) in Forest plots.   
When study design was sufficiently homogeneous, we combined studies in meta-analyses and meta-
regressions. Heterogeneity was measured with I2, the percentage of total variation attributable to true 
heterogeneity and not to chance [1, 2]. We used funnel plots to illustrate graphically presence of 
asymmetry and potential publication bias. We also used statistical tests to assess asymmetry formally 
[3], being cautious in their interpretation when significant degrees of heterogeneity (risk of false 
positive findings), limited number of available studies (lack of power of the test), and similar sample 
size of studies included in the meta-analysis (absence of meaningfulness of the test) were present [4]. 
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Evidence grading  
We ranked the evidence provided by RCTs and observational studies according to the GRADE 
criteria, rating evidence quality on a four-level scale ranging from “high” to “very low” [5] . RCTs 
provide default “high” quality that can be downgraded if bias or other limitations are present. 
Observational studies are initially rated as “low” quality but can be up- or down- graded depending 
on specific features. The GRADE system considers crucial adequate control for confounding which 
implies that when a model purpose is explanatory, at least most known prognostic factors should be 
measured and included in the model [6-8].  Although GRADE rating has been developed for bodies 
of evidence, we applied its evidence quality criteria first to single studies and proceeded with body 
evidence analysis only in a further step. According to GRADE rating, “very low” quality indicates 
that the degree of the estimate uncertainty of the documented effects is high and incompatible with 
substantially different true effects (including absence of any effect).  We provided a further quality 
assessment based on statistics reporting (“partial” or “sufficient for quality assessment”) and 
methodological/statistical quality (“low” or “high”). Finally, we verified the existence of external 
validity issues (“yes” or “no”).  
We rated evidence quality according to GRADE after verifying that the studies complied with three 
additional criteria: 1) high quality reporting (rated “partial” or “sufficient for quality assessment, as 
per Consolidated Standards of Reporting Trials CONSORT statement for RCTs [9]) and according 
to indications provided by literature for observational studies [10], 2) absence of methodological and 
statistical flaws (CONSORT recommendations) and 3) flaws that may affect observational studies, 
not detailed by the GRADE system such as risk of over-fitting when less than 10 outcomes per 
variable are available [11, 12], bivariate statistics tests used to screen variables for multivariable 
analysis [13], abuse of automatic variable selection procedures [14], not accounting for immortal-
time bias when dealing with time-dependent treatments [15], not balancing the probability of 
receiving a specific treatment with propensity scores [16], absence of external validity issues, such 
as specificity of case-mix, of treatment protocols, of health-care settings [17].  
If these criteria were not fulfilled we downgraded the GRADE rating.  
The review was conducted complying with the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) statement recommendations [18]. 
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Consensus methodology  
We used a modified Delphi process based on the integration of evidence provided by the literature 
and expert opinions. All the results of the GRADING of the evidence were available to the panel 
through a web-based file. The chairs (MO, GC) integrated the initial questions with literature revision 
and grading, and formulated 4 mutually exclusive questions and 35 questions (clustered in five 
different sections) requiring a score ranging from 1 (strongly disagree) to 10 (strongly agree). These 
questions were submitted to the members of the panel through a web-based system. For each question 
or cluster of questions the experts could provide comments to integrate their answers. The answers 
were analysed by a non-voting member of the panel (DP). Answers providing scores were analysed 
as medians, 20th, and 80th percentiles. Further, scores were clustered into low (1-3), intermediate (4-
7), and high (8-10), and analysed with correspondence analysis. Both approaches were used to spot 
answers that provided clear-cut positions among experts, particularly those polarized on agreement 
or disagreement. Correspondence analysis was used to assess if single members of the panel provided 
specific response patterns, especially when intermediate positions were taken. The results of the 
analyses were returned to the panel anonymously. The same list of question was then submitted to 
the panel in a second round. 
On the basis of the analysis of the second round of questions, statements were formulated by the 
chairs (MO, GC) selecting questions with higher degrees of agreement, and then submitted to the 
panel. Answers were analysed with correspondence analysis to spot heterogeneity among the panel 
members. Single panel members, who presented heterogeneous answer patterns, were provided 
feedbacks on their answers with request to confirm their vote, thereby allowing the detection of 
misinterpretations of some statements.  
A final vote was required for confirmation, with >80% of voting members necessary for a strong 
recommendation (for or against). When votes for or against (a mix of strong and weak options) 
reached the 80% threshold, then a weak recommendation was provided. In case of minor concerns 
panel members could declare reservation. In case of major concerns a stand aside position was 
adopted, no blocking option was permitted, and reasons for concerns were reported. 
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Figure ESM1. Meta-analysis of studies investigating balanced crystalloids vs. normal saline in 
reducing the risk of hyperchloremia. 
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Figure ESM2. Flow-chart illustrating the process for study selection to be included in the meta-
analysis and meta-regression, for examining the effectiveness of MAN and HTS in reducing 
ICP.  
The PubMed search identified 679 titles. Only observational studies were found (Tables SM 2 and 3). A total 
of 12 studies (n=190 patients) were analysed for MAN (8 investigated MAN only [36, 40, 43, 46-49, 53], 4 
MAN + HTS [38, 50, 55, 60]): for 1 study, in which three different doses were tested on the same patients at 
different times, the highest dose was chosen for inclusion in the analysis [46], and 1 study reported separate 
average measures for 4 subgroups of patients (therefore each subgroup was considered as an independent 
study) [48].  
A total of 10 studies (N=174 patients) were analysed for HTS (6 investigated HTS only [34, 44, 45, 52, 71, 
88], 4 HTS + MAN). The MAN studies investigated almost exclusively TBI patients (doses 0.25-1.0 mg/kg; 
ICP values were reported 10-60 minutes following bolus administration in 8 studies, whereas in 3 the lowest 
ICP value was recorded, and in 1 study the time of the ICP reading was not reported). The HTS investigated 
TBI in 6 studies and SAH in 2 studies (doses 100-1100 mOsmoL; in 6 studies ICP values were reported 60 
minutes following bolus administration, in 1 study at 30 minutes, in 1 study at 5 minutes, while in 2 studies 
the lowest ICP values were reported).
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Figure ESM3.  Funnel plot (to be specified) 
  
 
 
  
Random−Effects Model
Observed Outcome
S
ta
n
d
a
rd
 E
rr
o
r
1
3
.9
5
6
1
0
.4
6
7
6
.9
7
8
3
.4
8
9
0
−20 −10 0 10 20 30 40
p = 0.005
 
query and body of evidence grading 
 
Group 1 
Figure ESM4. Funnel plot (to be specified) 
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Table ESM 1. Efficacy of mannitol in reducing ICP, accounting for the initial ICP and the MAN 
dose.  
Results of the multivariable meta-regression analysis are shown using low and high correlation to 
calculate variance between before and after ICP measurements. 
  Low correlation High correlation 
  Estimate P value Estimate P value 
Intercept -13.0148 <.0001 -8.9545 0.1304 
Initial ICP 0.6958 <.0001 0.5866 <.0001 
Dose 6.3386 0.0623 5.214 0.3145 
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Table ESM 2. Generalized estimated equations (GEE) model examining the effect of mannitol 
on ICP reduction variation across studies.  
 
  
 
Estimates wald p 
Intercept 19.2 17.82 < 0.001 
ICP variation -9.9 -8.193 < 0.001 
Launey  [43] 16.7 8.963 < 0.001 
Muizelaar  [49] 1.2 0.9426 0.34 
Oddo  [50] 10.7 5.08 < 0.001 
Ware  [60] 12.6 3.462 < 0.001 
The reference study is Helbok et al. [40] 
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Table ESM 3. Generalized estimated equations (GEE) model examining the effect of mannitol 
on ICP reduction, according to baseline pre-treatment ICP. 
 
 Estimates wald p 
(Intercept) -4.46 -1.637 0.10 
ICP reduction 0.72 5.992 < 0.001 
Launey  [43] -8.61 -2.568 0.001 
Muizelaar [49] -3.84 -1.983 0.005 
Oddo [50] -7.62 -3.017 < 0.001 
Ware [60] 1.31 0.4505 0.65 
The reference is the Helbok et al. study [40]. 
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SG1 Q1 Is there evidence on efficacy and safety of crystalloid solutions compared to albumin, 
in the resuscitation of acute brain injury (TBI, SAH, ICH, severe MCA stroke)? 
 
One trial compared the efficacy of high dose albumin vs. saline bolus administered in two hours 
within five hours from ischemic stroke [1]. The study was interrupted prematurely for futility. 
Evidence from this study was graded high. We considered this study among those focused on 
resuscitation and not maintenance fluid administration.  
A previous observational study suggested that high dose albumin administered within 16 hours from 
ischemic stroke was strongly protective [2]. We graded this study as very low according to the 
GRADE and confirmed this grading in our final evaluation. 
Only these two studies were considered sufficiently homogeneous to contribute to the same body 
of evidence that was graded (high against effectiveness of high dose albumin in stroke). The 
following studies, instead, were too heterogeneous to be combined in an overall body of evidence. 
Their individual grading (reported in the quality assessment forms at the end of this document) 
hence corresponds to the body of evidence grading.  
A subgroup analysis from the SAFE trial, reported a striking higher rate of deaths at 24 months in 
TBI patients treated with albumin compared to saline.[3] As the result of a subgroup analysis the 
study can only be used for hypothesis generation, and was grades as low (GRADE and methodologist 
final evaluation). 
Finally, two observational studies investigating the use of albumin in SAH were downgraded to very 
low quality for several biases.[4, 5] Both studies dealt with fluid maintenance although the use of 
study fluids for resuscitation was not excluded. 
 
albumin in ischemic stroke – RCT 
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RCT	2
Year 2013 First	Author Ginsberg
Journal Lancet	Neurol
Sample Ischemic	stroke
Treatment High	dose	albumin	(2	gr/kg)	within	5	hours	from	stroke
Control Saline
Outcome NIHSS	and/or	mRS	0-1	at	90	(±	30)	days
n°	pz n %
Treatment 422 186 44.1
Control 419 185 44.2
Total 841 371 44.1
Centres 5	Centres
Power 0.026
GRADE	CRITERIA
Allocation	concealment Yes
Intention	to	treat	principle	observed Yes
Blinding Yes
Completement	of	follow-up Yes
Early	stopping Yes
Bias No
Statistical	reporting	 Sufficient	for	quality	assessment
Methodological	and	statistical	quality High
Indirectness No
Publication	bias No
Inconsistency	with	other	trials Not	assessable
Size	of	effect Not	relevant
Residual	confounding Not	assessable
Dose	/response Not	relevant
DETAILS
GRADE	rating High	evidence
Statistical	reporting	 Sufficient	for	quality	assessment
Methodological	and	statistical	quality High
External	validity	issues No
Final	grading No	grading	modification
Final	level	of	evidence High	evidence
Early	stopping:	For	futility	after	scheduled	interim	analysis;	
Methodological	and	statistical	quality:	To	have	a	0.84	power	to	detect	a	
10%	reduction	of	the	primary	outcome	a	sample	of	980	patients	was	
required.	Although	the	required	sample	size	was	not	reached,	it	is	
unlikely	that	a	clinically	significant	of	the	outcome;	D
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Outcome
NNTB	1300	(95%-CI	NNTB	15	to	∞	to	NNTH	15)
delta	-0.1	(95%-CI	-6.8	to	6.6)
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Observational 3 Very	low	evidence		-	No	grading	modification
Year 2006
Journal Stroke
First	Author Palesch
Statistical	method Logistic	regression
Inclusion	criteria
Treatment High	dose	albumin
Outcome
Good	outcome	(Rankin	scale	3-6	at	90	days):	40	(48.8%)
Centres 2 Variable:	OR	95%	CI
N°	patients/centre/year NA 	Albumin	HD/LD:	1.81	(1.11-2.94)
Study	duration	(days) NA
Total	(included	in	the	
model)
82
GRADE	CRITERIA
Statistical	reporting Sufficient	for	quality	assessment
Statistical	quality Low
Appropriate	eligibility	criteria Yes
Measurement	of	exposure Yes
Measurement	of	outcome Yes
	Adequate	control	for	
confounding
No
Bias No
GRADE		overall
Size	of	effect Not	relevant
Residual	confounding Does	not	indicate	upgrading
Dose	/response Not	applicable
DETAILS
D
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External	validity
GRADE	rating	up/down No	grading	modification
GRADE	rating Very	low	evidence
Statistical	reporting Sufficient	for	quality	assessment
Statistical	quality Low
External	validity	issues Yes
Final	grading Downgraded	study
Final	level	of	evidence Very	low	evidence
U
p
-
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g
Ischemic	stroke
	Adequate	control	for	confounding:	The	model	adjusted	only	for	tPA.	Statistical	quality:	Clearly	underfitted	
model	not	accounting	for	important	predictors	of	good	outcome.	
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Single	center	study
Conclusive	evaluation	
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RCT	1
Year 2007 First	Author Myburgh
Journal JAMA
Sample TBI	patients	from	the	SAFE	trial
Treatment 4%	albumin
Control 0.9%	saline
Outcome Good	outcome	(eGOS)	24	months	after	randomization
n°	pz n %
Treatment 214 71 33.2
Control 206 42 20.4
Total 420 113 26.9
Centres 16	Centres
Power 0.850
GRADE	CRITERIA
Allocation	concealment Yes
Intention	to	treat	principle	observed Yes
Blinding Yes
Completement	of	follow-up Yes
Early	stopping No
Bias very	serious
Statistical	reporting	
Sufficient	for	quality	
assessment
Indirectness No
Imprecision No
Publication	bias Not	assessable
Inconsistency	with	other	trials Not	assessable
Size	of	effect Not	relevant
Residual	confounding Not	assessable
Dose	/response Not	relevant
DETAILS
GRADE	rating Low	evidence
Statistical	reporting	
Sufficient	for	quality	
assessment
Methodological	and	statistical	quality High
External	validity	issues No
Final	grading Downgrading
Final	level	of	evidence Low	evidence
Outcome
NNTH	8	(95%-CI	NNTH	23	to	NNTH	5)
delta	12.8	(95%-CI	4.3	to	21)
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Bias:	The	study	is	a	subgroup	analysis	of	the	SAFE	trial.	In	
subgroup	analysis	the	benefits	of	randomization	cannot	be	
extended	to	subgroups	and	the	study	can	only	be	useful	for	
hypothesis	generation;	
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Observational	study 1 Very	low	evidence		-	Downgraded	study
Year 2013
Journal JN
First	Author Kuwabara
Statistical	method Logistic	regression	with	propensity	score	adjustment
Inclusion	criteria SAH	undergoing	surgical/interventional	procedures
Treatment Albumin	(from	procedure	to	the	4th	day)
Outcome
Hospital	mortality:	33	(0.6%)
Centres 550 Variable:	OR	95%	CI
N°	patients/centre/year NA Albumin	g/kg/day	(continuous)	Pre-DCI:	4.39	(0.9-21.37)
Study	duration	(days) 364 Albumin	g/kg/day	(continuous)	DCI:	2.55	(0.29-22.65)
Total	(included	in	the	
model)
5400
GRADE	CRITERIA
Statistical	reporting	 Partial
Statistical	quality Low
Appropriate	eligibility	criteria Yes
Measurement	of	exposure Yes
Measurement	of	outcome Yes
	Adequate	control	for	
confounding
Yes
Bias very	serious
GRADE		overall
Size	of	effect Large
Residual	confounding Does	not	indicate	upgrading
Dose	/response Not	applicable
DETAILS
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External	validity
GRADE	rating	up/down Downgraded	study
GRADE	rating Very	low	evidence
Statistical	reporting	 Partial
Statistical	quality Low
External	validity	issues No
Final	grading Downgraded	study
Final	level	of	evidence Very	low	evidence
Conclusive	evaluation	
No	external	validity	issues
U
p
-
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g
Size	of	effect:	High	imprecision,	result	statistically	not	significant.	
Bias:	Data	from	an	administrative	database	with	doubts	on	the	quality	of	clinical	data	and	missing	information.	
Statistical	quality:	The	4th	day	was	arbitrarily	considered	the	cut-off	for	delayed	cerebral	ischemia,	without	any	
direct	diagnosis.	This	assumption	substantially	biased	the	study.	The	reporting	is	confusing.	In	the	same	model	
we	absolute	doses	and	doses	adjusted	for	weight	are	included.	The	reported	ORs	are	not	consistent.	
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Observational	study 2 Very	low	evidence		-	Downgraded	study
Year 2004
Journal JN
First	Author Suarez
Statistical	method Logistic	regression
Inclusion	criteria
Treatment Albumin
Outcome
GOS	≥	4:	43	(51.2%)
Centres 1 Variable:	OR	(95%-CI)
N°	patients/centre/year 42 Albumin:	3.2	(1.1-11.0)
Study	duration	(days) 731
Total	(included	in	the	
model)
84
GRADE	CRITERIA
Statistical	reporting Partial
Statistical	quality Low
Appropriate	eligibility	criteria Yes
Measurement	of	exposure Yes
Measurement	of	outcome Yes
	Adequate	control	for	
confounding
No
Bias very	serious
GRADE		overall
Size	of	effect Large
Residual	confounding Does	not	indicate	upgrading
Dose	/response Not	applicable
DETAILS
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External	validity
GRADE	rating	up/down Downgraded	study
GRADE	rating Very	low	evidence
Statistical	reporting Partial
Statistical	quality Low
External	validity	issues Yes
Final	grading Downgraded	study
Final	level	of	evidence Very	low	evidence
Conclusive	evaluation	
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Single	center	study
SAH,	clipped	ruptured	aneurysm
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	Adequate	control	for	confounding:	Important	predictors	were	not	included	in	logistic	regression	(only	age,	sex,	
race,	GCS	<	9,	and	treatment	entered	the	model)..	Statistical	reporting:	Insufficient	information	on	how	the	model	
was	developed	(e.g.	variable	selection,	management	of	continuous	variables)	were	provided.	No	information	on	
the	fit	of	the	model	was	available..	Statistical	quality:	The	small	sample	size	hampered	the	development	of	a	
multivariable	approach	with	explanatory	purposes.	The	model	was	underfitted	but	it	could	not	include	more	
variables	because	of	the	risk	of	overfitting	(there	were	already	only	8	outcomes	per	variable).	No	propensity	score	
was	developed.	
Size	of	effect:	Large	protective	effect	generated,	however,	by	a	potentially	biased	model.	No	upgrading	indicated.	
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SG1 Q2 Is there evidence on efficacy and safety of crystalloid solutions compared to synthetic 
colloids (starches, gelofusin), in the resuscitation of acute brain injury (TBI, SAH, ICH, severe 
MCA stroke)? 
 
Q6 Are there any studies that have compared 2 or more amounts of maintenance fluids, in acute 
brain injury (TBI, SAH, ICH, severe MCA stroke), a more restrictive versus a more liberal strategy? 
 
Q7 Is there any evidence to support that aiming for a negative fluid balance is superior or inferior to 
aiming for a positive fluid balance, in acute brain injury (TBI, SAH, ICH, severe MCA stroke)? 
 
Studies were too heterogeneous to be combined in an overall body of evidence. Their individual 
grading (reported in the quality assessment forms at the end of this document) hence corresponds 
to the body of evidence grading.  
 
 
One observational study concerning patients with subarachnoid hemorrhage investigated the effect 
of colloid administration (plasma, dextran, starch, and/or albumin) and positive fluid balance during 
the delayed ischemic neurologic deficit (DIND) risk period (3-14 days) [1]. This study answered to 
 
albumin in SAH – OBS 
Group 1 
the maintenance Q6 and Q7 queries. The study adjusted for confounders using propensity score 
matching, low quality of evidence for observational studies was thus confirmed. 
A second observational study also targeted on subarachnoid hemorrhage, investigated the effect 
on outcome of colloids and crystalloids used as maintenance fluids reporting a significant increase 
of 6-month poor outcome with colloids and a protective effect of crystalloids [2]. The study, 
however, was downgraded to very low evidence because of relevant methodological biases. The 
study answered to the Q6 query. 
 Two studies investigated fluid balance influence on outcome in SAH patients [3, 4]. The studies 
were heterogeneous in terms of design but especially in terms of outcomes (a combined outcome 
of new stroke and hospital mortality in one case, 6-month GOS in the other). The second study, 
which did not appear to be substantially biases although it had some generalizability issues, 
indicated a significant influence of positive balance on long-term outcome. The study was graded 
low.  The other study was downgraded to very low. Both studies provided evidence for Q6 and Q7. 
Only one observational study dealt with fluid balance in TBI providing evidence for Q6 and Q7 [5]. 
The study had several shortcomings and insufficient reporting and was downgraded to very low. 
Finally, one observational study dealing with traumatic brain injury (TBI) patients investigated the 
effect of cumulative pentastarch doses [6]. This study answered query Q6 and was also downgraded 
to very low. No studies dealing specifically with resuscitation (query Q2) were found, although those 
dealing with maintenance were probably using the same fluid administration approach when 
resuscitation was required. 
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Observational	study 1
Year 2013
Journal NC
First	Author Ibrahim
Statistical	method Propensity	score	matching
Inclusion	criteria SAH
Treatment Colloids	(plasma,	dextran,	starch,	and/or	albumin)	
Outcome
Delayed	cerebral	infarcts:	60	(48.8%)
Centres 1 Delta	3.7	(95%-CI	-14.5	to	21.6)
N°	patients/centre/year NA NNTH	27	(95%-CI	NNTB	7	to	∞	to	NNTH	5)
Study	duration	(days) 365 p	=	0.71
Total	(included	in	the	
model)
123 power	0.057
GRADING	CRITERIA
Statistical	reporting	 Partial
Methodological	and	statistical	qualityHigh
Appropriate	eligibility	criteria Yes
Measurement	of	exposure Yes
Measurement	of	outcome Yes
	Adequate	control	for	
confounding
Yes
Bias No
Size	of	effect
Residual	confounding Does	not	indicate	upgrading
Dose	/response No
DETAILS
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External	validity
GRADE	rating	up/down Downgraded	study
GRADE	rating Low	evidence
Statistical	reporting	 Partial
Methodological	and	statistical	qualityHigh
External	validity	issues Yes
Final	grading Downgraded	study
Final	level	of	evidence Low	evidence
Conclusive	evaluation	
D
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Single	center	study
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Statistical	reporting	:	It	is	not	clear	which	formal	criteria	were	adopted	to	coestablish	the	adequacy	of	matching.	
Methodological	and	statistical	quality:	Undereporting	of	the	statistical	approach	that,	however,	appears	
substantially	correct.	Imprecision:	Statistically	non	significant	result.	Wide	range	of	the	confidence	interval.	
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Observational	study 2
Year 2008
Journal BJN
First	Author Tseng
Statistical	method Logistic	regression
Inclusion	criteria
Treatment Daily	colloid	(4%	succinylated	gelatine	or	6%	pentastarch)	dose	(L/day)
Outcome
Unfavourable	GOS	at	6	months:	52	(32.5%)
Centres NA Variable:	OR	95%-CI
N°	patients/centre/year NA
Daily	colloid	(4%	succinylated	gelatine	or	6%	pentastarch)	
dose	(L/day):	2.53	(1.13-5.68)
Study	duration	(days) 820
Total	(included	in	the	
model)
160 Variable:	OR2	(95%-CI)
Unfavourable	GOS	at	6	
months
52	(32.5%) Cristalloids	daily	dose	(L/day):	0.27	(0.11-0.67)
GRADING	CRITERIA
Statistical	reporting Partial
Statistical	quality Low
Appropriate	eligibility	criteria Yes
Measurement	of	exposure Yes
Measurement	of	outcome Yes
	Adequate	control	for	
confounding
Not	reported
Bias serious
Size	of	effect Large
Residual	confounding Does	not	indicate	upgrading
Dose	/response Not	applicable
DETAILS
D
o
w
n
gr
ad
in
g
U
p
-
gr
ad
in
g
External	validity
GRADE	rating	up/down Downgraded	study
GRADE	rating Very	low	evidence
Statistical	reporting	 Partial
Methodological	and	statistical	qualityLow
External	validity	issues No
Final	grading Downgraded	study
Final	level	of	evidence Very	low	evidence
Conclusive	evaluation	
NA
SAH	from	aneurysmal	rupture
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Statistical	reporting	:	The	variables	included	in	the	model	were	not	reported	and	insufficient	accounting	for	
confounders	could	not	be	ruled	out.	No	information	on	the	fit	of	the	model	was	available.	Methodological	and	
statistical	quality:	Undereporting.	.	
Size	of	effect:	No	upgrading	because	the	result	of	a	potentially	biased	model.	
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Observational	study 4
Year 2002
Journal CCM
First	Author Clifton
Statistical	method Logistic	regression
Inclusion	criteria
Treatment 96-hour	fluid	balance	<	minus	594	ml	after	enrollment	in	the	trial
Outcome
6-month	GOS	3-5:	211	(57.3%)
Centres 11 Variable:	OR	p	value
N°	patients/centre/year 9 96-hour	fluid	balance	<	minus	594:	NA	0.0048
Study	duration	(days) 1338
Total	(included	in	the	
model)
368
GRADING	CRITERIA
Statistical	reporting Partial
Statistical	quality Low
Appropriate	eligibility	criteria Yes
Measurement	of	exposure Yes
Measurement	of	outcome Yes
	Adequate	control	for	confounding No
Bias serious
Size	of	effect NA
Residual	confounding Does	not	indicate	upgrading
Dose	/response No
DETAILS
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External	validity
GRADE	rating	up/down No	grading	modification
GRADE	rating Low	evidence
Statistical	reporting	 Partial
Methodological	and	statistical	qualityLow
External	validity	issues No
Final	grading Downgraded	study
Final	level	of	evidence Very	low	evidence
Conclusive	evaluation	
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	Adequate	control	for	confounding:		Insufficient	number	of	variables	for	an	explanatory	model:	although	some	
important	variables	were	inlcuded	other	variables	concerning	overall	severity	were	omitted.	Statistical	reporting	:	No	
ORs	were	reported	but	only	p	values.	Methodological	and	statistical	quality:	The	model	was	underfitted..	
TBI	GCS	3-8
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Observational	study 5
Year 2012
Journal NC
First	Author Martini
Statistical	method Logistic	regression
Inclusion	criteria
Treatment 3-day	positive	fluid	balance
Outcome
Hospital	mortality	and	new	stroke:	117	(32.9%)
Centres 1 Variable:	OR	(95%-CI)
N°	patients/centre/year 63 3-day	positive	fluid	balance:	1.47	(0.85-2.54)
Study	duration	(days) 2071
Total	(included	in	the	
model)
356
GRADING	CRITERIA
Statistical	reporting Sufficient	for	quality	assessment
Statistical	quality Low
Appropriate	eligibility	criteria Yes
Measurement	of	exposure Yes
Measurement	of	outcome Yes
	Adequate	control	for	
confounding
No
Bias serious
Size	of	effect Not	relevant
Residual	confounding Does	not	indicate	upgrading
Dose	/response No
DETAILS
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External	validity
GRADE	rating	up/down Downgraded	study
GRADE	rating Very	low	evidence
Statistical	reporting	 Sufficient	for	quality	assessment
Methodological	and	statistical	qualityLow
External	validity	issues Yes
Final	grading Downgraded	study
Final	level	of	evidence Very	low	evidence
Conclusive	evaluation	
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	Adequate	control	for	confounding:	Variables	were	selected	a	according	to	an	a	priori	design.	Important	
predictors	however	were	not	included	in	the	model.	The	inclusion	of	troponin	in	the	model	was	not	explained.	
GCS	was	not	included	in	the	model	preferring	the	more	subjective	Hunt-Hess	and	Fisher	scores.	Methodological	
and	statistical	quality:	The	model	was	underfitted.	
SAH	patients
Single	center	study
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Observational 6
Year 2015
Journal JSCD
First	Author Kissoon
Statistical	method Logistic	regression	with	propensity	score	adjustment
Inclusion	criteria
Treatment Net	fluid	balance
Outcome
mRS	score	3-6:	0	(0%)
Centres 1 Variable:	OR	(95%-CI)
N°	patients/centre/year 30 Liter	increase	fluid	balance:	1.18	(1.08-1.29)
Study	duration	(days) 3559
Total	(included	in	the	
model)
288
GRADING	CRITERIA
Statistical	reporting Sufficient	for	quality	assessment
Statistical	quality High
Appropriate	eligibility	criteria Yes
Measurement	of	exposure Yes
Measurement	of	outcome Yes
	Adequate	control	for	
confounding
No
Bias serious
Size	of	effect Not	relevant
Residual	confounding Does	not	indicate	upgrading
Dose	/response Not	applicable
DETAILS
D
o
w
n
gr
ad
in
g
U
p
-
gr
ad
in
g
External	validity
GRADE	rating	up/down No	grading	modification
GRADE	rating Low	evidence
Statistical	reporting	 Sufficient	for	quality	assessment
Methodological	and	statistical	qualityHigh
External	validity	issues Yes
Final	grading No	grading	modification
Final	level	of	evidence Low	evidence
Conclusive	evaluation	
SAH
D
o
w
n
gr
ad
in
g
Single	center	study	carried	out	on	a	wide	time	span
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Observational 3
Year 2011
Journal JCC
First	Author Sekhon
Statistical	method Cox	proportional	hazards
Inclusion	criteria
Treatment Cumulative	pentstarch	volume
Control No	pentstarch Outcome
Hospital	mortality:	37	(21.6%)
Centres 1 Quintiles	pentastarch	(ref	1):	OR	(95%-CI)
N°	patients/centre/year 29 2:	1.4	(0.43-4.5)
Study	duration	(days) 2160 3:	1.1	(0.32-2.8)
Total	(included	in	the	
model)
171 4:	1.2	(0.34-4.1)
GRADING	CRITERIA
Statistical	reporting Sufficient	for	quality	assessment
Statistical	quality Low
Appropriate	eligibility	criteria Yes
Measurement	of	exposure Yes
Measurement	of	outcome Yes
	Adequate	control	for	confounding No
Bias very	serious
Size	of	effect Not	relevant
Residual	confounding Does	not	indicate	upgrading
Dose	/response No
DETAILS
D
o
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n
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g
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External	validity
GRADE	rating	up/down Downgraded	study
GRADE	rating Very	low	evidence
Statistical	reporting	 Sufficient	for	quality	assessment
Methodological	and	statistical	quality Low
External	validity	issues Yes
Final	grading Downgraded	study
Final	level	of	evidence Very	low	evidence
Conclusive	evaluation	
Single	center	study
U
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TBI	GCS	≤	8
	Adequate	control	for	confounding:	Overfitted	model.	Methodological	and	statistical	quality:	Hospital	mortality	is	not	a	
good	outcome	when	dealing	with	TBI.	The	model	was	clearly	overfitted	since	11	variables	were	included	when	only	37	
events	(hospital	deaths)	occured.	No	propensity	score	was	developed.	
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SG1 Q3 Is there evidence on efficacy and safety of balanced crystalloid solutions 
compared to sodium chloride, in the resuscitation of acute brain injury (TBI, SAH, 
ICH, severe MCA stroke)? 
 
Q8 Is there evidence on efficacy and safety of balanced crystalloid solutions compared 
to sodium chloride, as maintenance fluids in acute brain injury (TBI, SAH, ICH, severe 
MCA stroke)?  
 
 
 
No studies considered robust outcomes as survival and good neurological recovery. 
One RCT comparing hypertonic saline and ringer lactate solutions for resuscitation in 
TBI patients, reported significant higher serum sodium and osmolarity, but the 
average values were not reported and only illustrated in a graph. Eyeballing the plot 
it seems that average natremia and osmolarity were never higher than 148 meq/L and 
303 mOsm/L, respectively [1]. Evidence was downgraded because of methodological 
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drawbacks to low according to the GRADE classification. The final grading was 
however very low considering additional parameters as the insufficient reporting and 
risk overestimation related to the small sample size. The grading report form for this 
study is available in the SG1 Q4 file. 
We also retrieved two small RCTs investigating the effect on chloremia (a secondary 
outcome in our revision design) of balanced solutions vs. saline administered as 
continuous infusion to patients with SAH or TBI in the first 48 hours from admission 
[2, 3]. These studies are thus focused on early fluid administration for maintenance, 
but their use for resuscitation was not explicitly excluded. We thus considered them 
for both queries Q3 and Q8. Both studies showed a striking protective effect against 
hyperchloremia of balanced solutions. 
These two studies were downgraded to moderate because of their small sample size 
and imprecision according to the GRADE, and further downgraded to low applying 
criteria not specifically considered by the GRADE classification, in relation to the risk 
of having an inflated estimate of the true effect due to the limited sample size [4]. We 
considered the different kind of brain injuries objective of the studies were 
uninfluential on the degree of chloremia. Other important features were instead 
sufficiently consistent and homogenous to allow a meta-analytical approach. The 
overall body of evidence was considered moderate notwithstanding the high degree 
of imprecision due to the small sample size and the risk of inflated effect, because the 
results were strongly plausible and consistent between studies. Thus the protective 
effect of balanced solutions was judged highly probable although the quantitative 
assessment may have been overestimated. 
 
 
 
balanced solutions vs. saline in SAH – RCT 
Group 1 
 
RCT	1
Year 2013 First	Author Lehmann
Journal Neurosurgery
Sample SAH
Treatment balanced	crystalloid	and	colloid	solutions	for	48	h
Control normal	saline	and	hydroxyethyl	starch	for	48	h
Outcome Chloraemia	>	108	meq/L
n°	pz n %
Treatment 18 8 44.4
Control 18 16 88.9
Total 36 24 66.7
Centres Single	Center
Power 0.894
GRADE	CRITERIA
Allocation	concealment Not	reported
Intention	to	treat	principle	observed Not	reported
Blinding Yes
Completement	of	follow-up Yes
Early	stopping No
Bias No
Statistical	reporting	
Sufficient	for	quality	
assessment
Indirectness No
Imprecision very	serious
Publication	bias Not	assessable
Inconsistency	with	other	trials No
Size	of	effect Large
Residual	confounding Not	assessable
Dose	/response Not	relevant
DETAILS
GRADE	rating Moderate	evidence
Statistical	reporting	
Sufficient	for	quality	
assessment
Methodological	and	statistical	quality Low
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Low	evidence
Methodological	and	statistical	quality:	Very	small	sample	with	
high	chance	of	unbalances	in	important	prognostic	factors	
(measured	and	unmeasured)	between	the	two	study	arms.	No	
power	calculation	was	performed.	The	very	low	sample	size	
can	determin	an	exagerated	statistically	signficant	effect;	
Imprecision:	The	very	small	sample	size	determined	a	large	
confidence	interval;	
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NNTB	2	(95%-CI	NNTB	2	to	NNTB	7)
delta	-44.4	(95%-CI	-65.9	to	-13.7)
 
balanced solutions vs. saline in TBI – RCT 
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RCT	2
Year 2013 First	Author Roquilly
Journal CC
Sample TBI	(GCS	≤	8)	or	SAH
Treatment balanced	saline	and	hydroxyethyl	starch	for	48	h
Control normal	saline	and	hydroxyethyl	starch	for	48	h
Outcome Hyperchloraemic	acidosis
n°	pz n %
Treatment 20 10 50.0
Control 21 19 90.5
Total 41 29 70.7
Centres Single	Center
Power 0.881
GRADE	CRITERIA
Allocation	concealment Yes
Intention	to	treat	principle	observed Yes
Blinding Yes
Completement	of	follow-up Yes
Early	stopping No
Bias very	serious
Statistical	reporting	
Sufficient	for	quality	
assessment
Methodological	and	statistical	quality Low
Indirectness No
Publication	bias No
Inconsistency	with	other	trials No
Size	of	effect Not	relevant
Residual	confounding Not	assessable
Dose	/response Not	relevant
DETAILS
GRADE	rating Moderate	evidence
Statistical	reporting	
Sufficient	for	quality	
assessment
Methodological	and	statistical	quality Low
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Low	evidence
Methodological	and	statistical	quality:	Very	small	sample	with	
high	chance	of	unbalances	in	important	prognostic	factors	
(measured	and	unmeasured)	between	the	two	study	arms.	No	
power	calculation	was	performed.	The	very	low	sample	size	
can	determin	an	exagerated	statistically	signficant	effect;	
Imprecision:	The	very	small	sample	size	determined	a	large	
confidence	interval;	
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NNTB	2	(95%-CI	NNTB	2	to	NNTB	8)
delta	-40.5	(95%-CI	-61.7	to	-12.6)
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balanced solutions vs. saline in TBI and SAH – metanalysis 
Group 1 
 
 
 
 
RE Model
0.05 0.25 1 4
Relative Risk (log scale)
Roquilly, 2013
Lehmann, 2013
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20
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58.1
41.9
0.55 [0.35, 0.88]
0.50 [0.29, 0.86]
0.53 [0.37, 0.75]
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Balanced Normal
Author and Year
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= 0 ( 95%−CI  0  − 99 )
p = 0.00038
Q = 0.076 p = 0.782
Risk of hyperchloremia
 
query and body of evidence grading 
Group 1 
 
References 
 
1. Shackford SR, Bourguignon PR, Wald SL, Rogers FB, Osler TM, Clark DE, 
(1998) Hypertonic saline resuscitation of patients with head injury: a 
prospective, randomized clinical trial. The Journal of trauma 44: 50-58 
2. Lehmann L, Bendel S, Uehlinger DE, Takala J, Schafer M, Reinert M, Jakob 
SM, (2013) Randomized, double-blind trial of the effect of fluid 
composition on electrolyte, acid-base, and fluid homeostasis in patients 
early after subarachnoid hemorrhage. Neurocritical care 18: 5-12 
3. Roquilly A, Loutrel O, Cinotti R, Rosenczweig E, Flet L, Mahe PJ, Dumont R, 
Marie Chupin A, Peneau C, Lejus C, Blanloeil Y, Volteau C, Asehnoune K, 
(2013) Balanced versus chloride-rich solutions for fluid resuscitation in 
brain-injured patients: a randomised double-blind pilot study. Critical 
care 17: R77 
4. Ioannidis JP, (2008) Why most discovered true associations are inflated. 
Epidemiology 19: 640-648 
 
 
 
 
SG1 Q4 Is there evidence on efficacy and safety of hypertonic solutions compared to 
isotonic solutions, in the resuscitation of acute brain injury (TBI, SAH, ICH, severe 
MCA stroke)? 
 
Studies were too heterogeneous to be combined in an overall body of evidence. Their 
individual grading (reported in the quality assessment forms at the end of this 
document) hence corresponds to the body of evidence grading.  
 
Two RCTs using different hypertonic solutions in severe TBI, but focused on the same 
outcome (early GOS) were found.[1, 2] One study comparing 1.6% hypertonic saline 
to ringer lactate for resuscitation purposes did not report blinding was seriously biased 
(downgrading to low quality according to the GRADE classification).[2] We further 
downgraded the study to very low because of statistical underreporting, absence of 
power calculation, and high risk of unbalances in important prognostic factors 
between the study arms because of the small sample size. The second study 
investigated 7.5%/6% dextrane solutions compared to normal saline.[1] According to 
the GRADE the study was graded as moderate, but downgraded to low in our final 
evaluation, for the same reasons that led to downgrade the previous study. 
 
query and body of evidence grading 
Group 1 
Finally, we found RCT comparing 7.5% hypertonic saline and ringer lactate bolus in the 
prehospital setting in severe head trauma.[3] The trial was of high quality according 
to the GRADE and to our final evaluation. 
 
 
hypertonic saline vs. ringer lactate in TBI – RCT 
Group 1 
 
 
hypertonic saline vs. ringer lactate in TBI – RCT 
Group 1 
RCT	1
Year 1998 First	Author Shackford
Journal JT
Sample TBI	any	GCS
Treatment 1.6%	hypertonic	saline	for	resuscitation		
Control Ringer	lactate	for	resuscitation		
Outcome GOS	at	hospital	discharge
n°	pz GOS	at	hospital	discharge
mean SD
Treatment 18 2.7 0.9
Control 16 2.5 0.8
Total 34 0.2 0.0
Centres 2	Centres
Power 0.096
GRADE	CRITERIA
Allocation	concealment Not	reported
Intention	to	treat	principle	observed Not	reported
Blinding Not	reported
Completement	of	follow-up Yes
Early	stopping Not	reported
Bias very	serious
Statistical	reporting	 Partial
Indirectness No
Imprecision Not	assessable
Publication	bias Not	assessable
Inconsistency	with	other	trials Not	assessable
Size	of	effect Not	assessable
Residual	confounding Not	assessable
Dose	/response Not	investigated
DETAILS
GRADE	rating Low	evidence
Statistical	reporting	 Partial
Methodological	and	statistical	quality Low
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Very	low	evidence
Bias:	No	reporting	of	allocation	concealment	or	blinding	
although	technically	possible;	Methodological	and	statistical	
quality:	No	reporting	on	how	randomization	was	performed.	
Very	small	sample	with	high	chance	of	unbalances	in	
important	prognostic	factors	(measured	and	unmeasured)	
between	the	two	study	arms,	as	demonstrated	by	the	
evidence	lower	mean	GCS	in	the	study	group	(p	=	0.057).	No	
sample	size	calculation	based	on	power	and	effect	size	was	
performed.	In	neurointensive	studies	longterm	(i.e.	6	or	12	
months)	GOS	should	be	the	outcome	of	choice;	
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hypertonic saline vs. normal saline in TBI – RCT 
Group 1 
 
 
RCT	2
Year 2009 First	Author Baker
Journal JNT
Sample TBI	GCS	≤	8
Treatment 7.5	saline/6%	dextran	250	ml	(single	resuscitation	dose)	
Control 0.9%	saline	250	ml	(single	resuscitation	dose)	
Outcome GOS	at	hospital	discharge	or	at	30	days
n°	pz
mean SD
Treatment 31 3.3 1.4
Control 33 3.3 1.4
Total 64 0 0.0
Centres Single	Center
Power NA
GRADE	CRITERIA
Allocation	concealment Not	reported
Intention	to	treat	principle	observed Not	reported
Blinding Yes
Completement	of	follow-up Yes
Early	stopping Yes
Bias serious
Statistical	reporting	 Partial
Methodological	and	statistical	quality Low
Indirectness No
Publication	bias Not	assessable
Inconsistency	with	other	trials Not	assessable
Size	of	effect Not	assessable
Residual	confounding Not	assessable
Dose	/response Not	investigated
DETAILS
GRADE	rating Moderate	evidence
Statistical	reporting	 Partial
Methodological	and	statistical	quality Low
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Low	evidence
Bias:	Allocation	concealment	was	not	reported;	
Methodological	and	statistical	quality:	Sample	size	
calculations	were	not	performed.	Very	small	samle	with	high	
risk	of	unbalances	between	study	and	control	group.	The	
attempt	to	adjust	for	confounders	with	a	multivariable	
analysis	was	limited	by	the	small	sample	size	(risk	of	
overfitting)	and	only	age,	initial	GCS	and	three	biomarkers	
were	included.	The	statistical	reporting	concerning	this	
analysis	was	too	scanty.	In	neurointensive	studies	longterm	
(i.e.	6	or	12	months)	GOS	should	be	the	outcome	of	choice;	
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hypertonic saline vs. ringer lactate– RCT 
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RCT	3
Year 2004 First	Author Cooper
Journal JAMA
Sample TBI	GCS	≤	8	and	SAP	<	100	mmHg
Treatment Prehospital	250	ml	hypertonic	saline	7.5%		
Control Prehospital	250	ml	ringer	lactate		
Outcome 6-months	GOSE
n°	pz
median IQR
Treatment 113 5 (3-6)
Control 113 5 (5-6)
Total 226 0 0
Centres 12
Power not	available
GRADE	CRITERIA
Allocation	concealment Yes
Intention	to	treat	principle	observed Yes
Blinding Yes
Completement	of	follow-up Yes
Early	stopping No
Bias No
Statistical	reporting	
Sufficient	for	quality	
assessment
Methodological	and	statistical	quality High
Indirectness No
Publication	bias Not	assessable
Inconsistency	with	other	trials Not	assessable
Size	of	effect Not	assessable
Residual	confounding Not	assessable
Dose	/response Not	investigated
DETAILS
GRADE	rating High	evidence
Statistical	reporting	
Sufficient	for	quality	
assessment
Methodological	and	statistical	quality High
External	validity	issues No
Final	grading No	grading	modification
Final	level	of	evidence High	evidence
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SG2 Q1 Efficacy: do we have osmotic drugs capable of reducing ICP? 
 
Body of evidence evaluation according to the GRADE classification: low. 
Final evaluation of body of evidence according to integrative parameters: low. 
 
Only one trial tested sodium lactate against placebo in TBI comatose patients. 
Evidence was downgraded to moderate according to the GRADE criteria but was 
further downgraded to low when considering other parameters the GRADE does not 
account for. 
Numerous observational studies dealing with mannitol or hypertonic saline for 
intracranial hypertension treatment in cerebral injuries were found, none of which 
had sufficient quality and enrolled a sufficient number of patients. We only included 
studies in which either mannitol or hypertonic saline was administered to adult 
patients (i.e. those older than 17 years of age) with ICP monitoring before and after 
osmotic agent administration. No study made adjustments for confounders. 
We thus selected those studies with a before-after design reporting ICP values as 
means and standard deviations, to perform our analysis [1-27]. We further selected 
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those studies that did not perform repeated administration of mannitol or hypertonic 
saline, because we could not account for repeated measures (tables 1 and 2). 
After the selection process was concluded, eight studies were available for analysis in 
the mannitol group [3-7, 9, 14, 19] plus four that investigated both mannitol and 
hypertonic saline [2, 8, 12, 13]. One study reported separate average measures for 
four subgroups of patients, so we considered each subgroup as an independent study 
[19]. 
Overall, fifteen different studies/patient-clusters and 190 patients were included in 
the meta-analysis and meta-regression (SM fig. 1). In one study, in which three 
different doses were tested on the same patients at different times, we arbitrarily 
chose the highest dose for inclusion in this analysis [5]. 
Six studies investigating only hypertonic saline remained after the inclusion criteria 
were applied [20-22, 25, 28, 29]. The meta-analysis and meta-regression was 
performed on a total of ten studies after adding the four that investigated both 
osmotic agents, resulting in 174 patients being included in the hypertonic saline 
analysis (SM fig. 1). 
Most studies investigated the effectiveness of both osmotic drugs in patients with TBI. 
The overall effectiveness of the two osmotic agents in reducing ICP was assessed 
using a meta-analytical approach. The meta-analysis required knowledge of the 
average difference in ICP measured before and after osmotic drugs administration and 
its sampling variance, but this information was not available for most studies. 
Sampling variance can be calculated with the following equation: 
 𝑣𝑖 =  
𝑠𝑑𝑖2
𝑛𝑖
,  
where 𝑠𝑑𝑖 =  √𝑠𝑑1𝑖2 + 𝑠𝑑2𝑖2 − 2 ×  𝑟𝑖 ×  𝑠𝑑1𝑖 ×  𝑠𝑑2𝑖,  
𝑠𝑑1𝑖 and 𝑠𝑑2𝑖 are the standard deviation of the outcomes at time 1 and 2 (i.e. 
before and after osmotic agent administration), 𝑟𝑖 is the correlation between the 
outcomes at the two-time points, and 𝑛𝑖 is the number of treated patients [30]. As 𝑟𝑖 
was not available for most studies, we tested two extremes correlation values, 0.1 and 
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0.9, focusing on the results of the first and using the second, less conservative in terms 
of variance calculation, as a sensitivity analysis. 
We performed two analyses on each group of studies, using low (0.1) or high (0.9) 
correlations between before and after measurements to compute the sampling 
variance, since we did not have single studies individual measurements to calculate 
the exact correlation. 
Our results are presented in terms of meta-analysis that has several limits, especially 
heterogeneity of the studies, the paucity of the information available, aside from the 
intrinsic limits of the meta-analytical approach. 
In our analysis mannitol and hypertonic saline turned out to be effective in reducing 
ICP (figures 1 to 4). Heterogeneity was high and statistically significant.  
Although we are dealing with observational studies there are several strengths of our 
approach parameters First, there is strong plausibility that osmotic drugs are effective 
in treating intracranial hypertension because of their pharmacokinetics and 
pharmacodynamics properties [31]. Second, the effects of osmotherapy in clinical 
practice are evident and reproducible, and this is probably the reason why clinicians 
continue to use mannitol despite strong warnings against its use in the literature. 
Third, there is very high consistency among studies that report the ICP-reducing 
effects of osmotic agents and, fourth, although observational, these studies adopted 
a before-after design that has several strengths in their relevance to clinical practice. 
In general, they have the advantage of testing the effects of therapy in the same 
patient, thus accounting for many patient-related variables. Moreover, in the specific 
case of intracranial hypertension, they are carried out over a short time frame when 
other conditions that could influence ICP have a high probability of remaining 
constant. 
In this context, the role of our analysis is to highlight the consistency of results across 
different studies, as confirmed by the multivariable approach carried out at an 
individual patient level (although controlling only roughly for centre case-mix and 
performance). 
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A limitation of our analysis is that we could not account for other interventions that 
might have been performed simultaneously with osmotic drugs administration in 
situations when ICP had increased to dangerously high levels, such as deepening 
sedation, draining cerebral-spinal fluid, moderate hyperventilation the patient, or 
optimizing systemic arterial pressure. Notwithstanding this limitation we argue that 
the evidence provided by our study, although low according to the GRADE scale, is 
sufficient to recommend the use of mannitol for the treatment intracranial 
hypertension and that its use could also reasonably be extended to other clinical 
conditions besides TBI such as subarachnoid haemorrhage or stroke. It goes without 
saying that the potential adverse effects of mannitol, such as hypovolemia and 
osmolarity derangements, must be prevented or treated in all cases. 
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First author, Year patients N 
dose 
(g/Kg) 
ICP measurement 
time after bolus 
(min) 
initial 
ICP 
(mmHg) 
ICP 
Reduction 
(mmHg) 
Marshall, 1978 [5] TBI 8 1 lowest 44 26 
Helbok, 2011 [3] SIH 11 1 60 19.3 7.1 
Muizelaar 1984 [7] TBI 31 0.66 25 18 4.2 
Mendelow1985 [6] TBI 41 0.25-0.5 10-20 21.9 4.7 
Rosner 1987 [9] 
TBI, ICH (3 Pts), 
neoplasia (1 Pt) 
16 1 Lowest 31 15 
Miller 
1993 [19] 
TBI 5 0.5 NA 37.8 17.4 
Miller 1993 [19] TBI 3 0.5 Na 44.7 11 
Miller 1993 [19] TBI 5 0.5 Na 36.8 13.2 
Miller 1993 [19] TBI 4 0.5 Na 58.7 14.5 
Launey 2014 [4] TBI , SAH (3 Pts) 13 0.5 20 38.4 14.7 
Oddo 2009 [8] TBI 10 0.75 30 30.2 9.1 
Ware 2005 [12] TBI 19 
0.86 
(mean) 
Lowest 35.9 20.9 
Francony 2008 [2] TBI, SIH, ISC* 10 0.6 60 31 14 
Scalfani 2012 [13] TBI 8 1 60 22.4 6.7 
Diringer 2012 [14] TBI 6 1 60 21.5 7.8 
Table 1: observational studies with a before-after design investigating the efficacy of mannitol in patients with 
cerebral injuries and increased intracranial pressure.
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First author, Year patients N % 
 HS 
(ml) 
mOsmol 
dose 
ICP 
measurement 
time after 
bolus (min) 
initial 
ICP 
(mmHg) 
ICP 
Reduction 
(mmHg) 
Ware, 2005 [12] TBI 13 23.4 30 240 Lowest 36 16 
Francony, 2008 
[2] 
TBI 10 7.45 100 254 60 27 10 
Scalfani, 2012 
[13] 
TBI 8 23.4 48 * 384 60 22.4 6.7 
Roquilly, 2011 
[21] 
TBI 50 20 NA Na 60 31 10 
Bentsen, 2006 
[22] 
TBI 22 7.2 140 § 344 Lowest 15.1 3.3 
Al-Rawi, 2010 
[28] 
SAH 16 23.5 140 § 1125 60 17.5 12.1 
Major, 2015 [20] TBI 15 30 10 102 60 28.8 10.4 
Al-Rawi, 2005 
[29] 
SAH 14 23.5 140 § 1125 60 20.8 14.9 
Oddo, 2009 [8] TBI 12 7.5 250 641 30 27.3 9.9 
Lescot, 2006 [25] TBI 14 20 40 273 5 23 6 
Table 2: observational studies with a before-after design investigating the efficacy of hypertonic saline in patients 
with cerebral injuries and increased intracranial pressure. 
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Figure 1: meta-analysis of studies investigating mannitol efficacy in reducing ICP, low correlation between 
before-after measures was used for variance calculation. 
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Figure 2: meta-analysis of studies investigating mannitol efficacy in reducing ICP, high correlation between 
before-after measures was used for variance calculation. 
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Figure 3: meta-analysis of studies investigating hypertonic saline efficacy in reducing ICP, low correlation 
between before-after measures was used for variance calculation. 
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Figure 4: meta-analysis of studies investigating hypertonic saline efficacy in reducing ICP, high correlation 
between before-after measures was used for variance calculation. 
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sodium lactate vs. 0.9% saline - RCT  
Group 2 
 
RCT	1
Year 2013 First	Author Ichai
Journal ICM
Sample TBI	GCS	≤	8	
Treatment Sodium	lactate	1100	mosm/kg	0.5	ml/Kg/h
Control 0.9%	saline	286	mosm/kg	0.5	ml/Kg/h
Outcome ICP	episodes	>	20	mmHg	and	>	10	min	during	the	48-hour	infusion
n°	pz n %
Treatment 30 11 36.7
Control 30 20 66.7
Total 60 31 51.7
Centres 2	Centres
Power 0.683
GRADE	CRITERIA
Allocation	concealment Yes
Intention	to	treat	principle	observed Yes
Blinding Yes
Completement	of	follow-up Yes
Early	stopping No
Bias No
Indirectness No
Imprecision serious
Publication	bias Not	assessable
Inconsistency	with	other	trials Not	assessable
Size	of	effect Not	relevant
Residual	confounding Not	assessable
Dose	/response Not	relevant
DETAILS
GRADE	rating Moderate	evidence
Statistical	reporting	
Sufficient	for	quality	
assessment
Methodological	and	statistical	quality Low
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Low	evidence
Methodological	and	statistical	quality:	Small	sample	with	high	
chance	of	unbalances	in	important	prognostic	factors	(measured	
and	unmeasured)	between	the	two	study	arms	and	a	high	risk	of	
overoptimistic	estimates;	Imprecision:	There	is	a	45%	relative	risk	
reduction,	with	wide	confidence	intervals,	and	a	sample	size	below	
the	GRADE	optimal	information	size	threshold;	
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Outcome
NNTB	3	(95%-CI	NNTB	2	to	NNTB	21)
delta	-30	(95%-CI	-50.4	to	-4.8)
 
7.2% saline in 200/0.5 HSS vs. 0.9% saline - RCT  
Group 2 
 
 
RCT	1
Year 2006 First	Author Bentsen
Journal CCM
Sample SAH	with	normal	ICP
Treatment 7.2%	saline	in	200/0.5	HSS	2	ml/kg	
Control 0.9%	saline	2	ml/kg	
Outcome ICP	reduction	difference
n°	pz
mean SD
Treatment 11 3.3 2.6
Control 11 0.3 1.3
Total 22 3 0.0
Centres Single	Center
Power 0.902
GRADE	CRITERIA
Allocation	concealment Not	reported
Intention	to	treat	principle	observed Yes
Blinding No
Completement	of	follow-up Yes
Early	stopping No
Bias very	serious
Statistical	reporting	 Sufficient	for	quality	assessment
Indirectness No
Imprecision Not	assessable
Publication	bias Not	assessable
Inconsistency	with	other	trials Not	assessable
Size	of	effect Not	assessable
Residual	confounding Not	assessable
Dose	/response Not	investigated
DETAILS
GRADE	rating Low	evidence
Statistical	reporting	 Sufficient	for	quality	assessment
Methodological	and	statistical	quality Low
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Very	low	evidence
Bias:	No	reporting	of	allocation	concealment,	no	blinding	was	
performed	although	technically	possible;	Methodological	and	
statistical	quality:	Very	small	sample	with	high	chance	of	unbalances	in	
important	prognostic	factors	(measured	and	unmeasured)	between	
the	two	study	arms.		No	sample	size	calculation	based	on	power	and	
effect	size	was	performed.	Limited	clinical	relevance	because	ICP	was	
low	in	the	patients	and	the	ICP	reduction	consequently	low;	
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p	value	0.004
ICP	reduction
 
query and body of evidence grading 
Group 2 
 
  
 
 
 
Observational	study 1 Very	low	evidence		-	Downgraded	study
Year 2013
Journal JT
First	Author Cooper
Statistical	method linear	mixed	model	with	random	intercept
Inclusion	criteria TBI	patients	from	the	SAFE	trial
Treatment 4%	albumin
Control 0.9%	saline Outcome
ICP	increase:	33	(19.9%)
Centres 16 Variable:	Slope	(mmHg/day)	SD
N°	patients/centre/year NA 4%	albumin:	1.31	0.33
Study	duration	(days) 606 0.9%	saline:	-0.37	0.36
Total	(included	in	the	
model)
166
GRADE	CRITERIA
Statistical	reporting	 Sufficient	for	quality	assessment
Statistical	quality Low
Appropriate	eligibility	criteria Yes
Measurement	of	exposure Yes
Measurement	of	outcome Yes
	Adequate	control	for	
confounding
No
Bias very	serious
GRADE		overall
Size	of	effect Not	relevant
Residual	confounding Does	not	indicate	upgrading
Dose	/response Not	applicable
DETAILS
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External	validity
GRADE	rating	up/down Downgraded	study
GRADE	rating Very	low	evidence
Statistical	reporting	 Sufficient	for	quality	assessment
Statistical	quality Low
External	validity	issues No
Final	grading Downgraded	study
Final	level	of	evidence Very	low	evidence
Conclusive	evaluation	
No	external	validity	issues
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Statistical	quality:	The	study	is	a	subgroup	analysis	of	the	SAFE	trial,	as	such	the	benefits	of	ramdomization	
applied	to	the	entire	study	sample	cannot	be	extended	to	the	TBI	subgroup.	Lineare	regressions		has	
explanatory	purposes	but	it	include	only		age,	GCS,	arterial	pressure,	and	CT	evidence	of	subarachmoid	
hemorrhage	for	mortality	prediction	(probable	underfitting).	Finally,	although	investigating	a	treatment		a	
propensity	score	is	not	applied	to	account	for	selection	bias.	
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query and body of evidence grading 
Group 2 
SG2 Q2: Efficacy: in TBI, is there evidence that osmotic drugs have different 
efficacy (more effective or less effective in reducing ICP) 
 
Studies were too heterogeneous to be combined in an overall body of evidence. Their 
individual grading (reported in the quality assessment forms at the end of this 
document) hence corresponds to the body of evidence grading.  
 
 
We found nine RCTs comparing different osmotic fluids in different clinical conditions. 
Six studies dealt exclusively with TBI,[1-6] two with TBI or non-traumatic 
haemorrhage,[7, 8] and one with ischemic stroke.[9] 
All studies compared hypertonic saline with mannitol,[1, 2, 4-9] besides one that 
compared sodium lactate and mannitol.[3] 
All the studies enrolled very few patients generating a bias due to the small sample 
sizes (i.e. low power to detect clinically relevant differences, the “winner curse” risk, 
the high probability of unbalances of important prognostic factors between study 
arms). Other important biases were also detected. Their heterogeneity in terms of 
design, especially treatment protocols, advised against the meta-analytical 
combination. 
Only one trial investigated sodium lactate vs. mannitol in severe TBI patients. 
All studies evidence was downgraded to low, according to the GRADE and our 
supplemental criteria. 
 
hypertonic saline vs. mannitol – RCT 
Group 2 
 
RCT	1
Year 2003 First	Author Vialet
Journal CCM
Sample TBI	with	persistent	coma	and	ICP	>	25	mmHg	
Treatment 7.5%	hypertonic	saline	2400	mosm/kg	2	ml/Kg
Control 20%	mannitol	1160	mosm/kg	2	ml/Kg
Outcome number	of	ICP	>	25	mmHg	episodes
n°	pz N	episodes/day
mean SD
Treatment 10 13.3 14.2
Control 10 6.8 5.5
Total 20 6.5 0.0
Centres Single	Center
Power NA
GRADE	CRITERIA
Allocation	concealment Not	reported
Intention	to	treat	principle	observed Not	reported
Blinding No
Completement	of	follow-up Yes
Early	stopping No
Bias very	serious
Statistical	reporting	 Partial
Indirectness No
Imprecision Not	assessable
Publication	bias Not	assessable
Inconsistency	with	other	trials Not	assessable
Size	of	effect Not	assessable
Residual	confounding Not	assessable
Dose	/response Not	investigated
DETAILS
GRADE	rating Low	evidence
Statistical	reporting	 Partial
Methodological	and	statistical	quality Low
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Low	evidence
Outcome
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p	=	0.02
Bias:	No	reporting	of	allocation	concealment,	no	blinding	was	
performed	although	technically	possible;	Methodological	and	
statistical	quality:	The	study	compares	non	equimolar	doses,	
favouring	hypertonic	saline.	Very	small	sample	with	high	
chance	of	unbalances	in	important	prognostic	factors	
(measured	and	unmeasured)	between	the	two	study	arms.		
No	sample	size	calculation	based	on	power	and	effect	size	was	
performed;	
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hypertonic saline vs. mannitol – RCT 
Group 2 
 
RCT	2
Year 2005 First	Author Battison
Journal CCM
Sample TBI	or	SAH	with	ICP	>	20	mmHg
Treatment 7.5	saline/6%	dextran		2498	mosm/kg	100	ml
Control 20%	mannitol		1245	mosm/kg	200	ml
Outcome ICP	reduction
n°	pz
median 95%-CI
Treatment 9 7.5 NA
Control 9 13 NA
Total 9	(crossover) -5 (-10.8;	-3)
Centres Single	Center
Power NA
GRADE	CRITERIA
Allocation	concealment Yes
Intention	to	treat	principle	observed Yes
Blinding No
Completement	of	follow-up Yes
Early	stopping Yes
Bias very	serious
Statistical	reporting	
Sufficient	for	quality	
assessment
Methodological	and	statistical	quality Low
Indirectness No
Publication	bias Not	assessable
Inconsistency	with	other	trials Not	assessable
Size	of	effect Not	assessable
Residual	confounding Not	assessable
Dose	/response Not	investigated
DETAILS
GRADE	rating Low	evidence
Statistical	reporting	
Sufficient	for	quality	
assessment
Methodological	and	statistical	quality Low
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Low	evidence
Outcome
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Bias:	No	blinding	was	performed	although	technically	
possible;	Methodological	and	statistical	quality:	Crossover	
trial:	potentially	treatment	was	provided	in	different	moments	
of	cerebral	injuries	evolution.	Very	small	sample	with	high	
chance	of	unbalances	in	important	prognostic	factors	
(measured	and	unmeasured)	between	the	two	study	arms.	No	
sample	size	calculation	based	on	power	and	effect	size	was	
performed;	
 
hypertonic saline vs. mannitol – RCT 
Group 2 
 
RCT	3
Year 2008 First	Author Francony
Journal CCM
Sample TBI	with	sustained	ICP	>	20	mmHg
Treatment 7.45%	hypertonic	saline	2548	mosm/kg	100	ml
Control 20%	mannitol	1100	mosm/kg	231	ml
Outcome Percentage	ICP	reduction
n°	pz
mean SD
Treatment 10 31 6.0
Control 10 27 3.0
Total 20 4 0
Centres 2
Power 0.416
GRADE	CRITERIA
Allocation	concealment Yes
Intention	to	treat	principle	observed Yes
Blinding No
Completement	of	follow-up Yes
Early	stopping No
Bias very	serious
Statistical	reporting	
Sufficient	for	quality	
assessment
Methodological	and	statistical	quality Low
Indirectness No
Publication	bias Not	assessable
Inconsistency	with	other	trials Not	assessable
Size	of	effect Not	assessable
Residual	confounding Not	assessable
Dose	/response Not	investigated
DETAILS
GRADE	rating Low	evidence
Statistical	reporting	
Sufficient	for	quality	
assessment
Methodological	and	statistical	quality Low
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Low	evidence
Outcome
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%	ICP	reduction	at	60	min
p	0.06
Bias:	No	blinding	was	performed	although	technically	
possible;	Methodological	and	statistical	quality:	Very	small	
sample	with	high	chance	of	unbalances	in	important	
prognostic	factors	(measured	and	unmeasured)	between	the	
two	study	arms,	no	reporting	of	blinding.	The	effect	size	used	
for	sample	size	calculation	was	very	large	(40%	reduction	in	
favour	of	hypertonic	saline),	with	a	high	risk	of	
overestimation.;	
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hypertonic saline vs. mannitol – RCT 
Group 2 
 
RCT	4
Year 2005 First	Author Harutjunyan	
Journal CC
Sample Neurosurgical	patients	with	TBI,	SAH,	or	IPH	and	ICP	>	20	mmHg
Treatment 7.2%	NaCl/HES	200/0.5		(2440	mOsm/Kg)	1.4	ml/Kg
Control 15%	mannitol	(870	mOsm/Kg)	1.8	ml/Kg
Outcome %	ICP	reduction
n°	pz
% SD
Treatment 17 57 NA
Control 15 48 NA
Total 32 9
Centres 1
Power not	available
GRADE	CRITERIA
Allocation	concealment Not	reported
Intention	to	treat	principle	observed Yes
Blinding No
Completement	of	follow-up Yes
Early	stopping No
Bias very	serious
Statistical	reporting	 Partial
Methodological	and	statistical	quality Low
Indirectness No
Publication	bias Not	assessable
Inconsistency	with	other	trials Not	assessable
Size	of	effect Not	assessable
Residual	confounding Not	assessable
Dose	/response Not	investigated
DETAILS
GRADE	rating Low	evidence
Statistical	reporting	 Partial
Methodological	and	statistical	quality Low
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Low	evidence
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Bias:	No	blinding	was	performed	although	technically	possible;	
Methodological	and	statistical	quality:	Very	small	sample	with	high	
chance	of	unbalances	in	important	prognostic	factors	(measured	
and	unmeasured)	between	the	two	study	arms.	No	sample	size	
calculation	based	on	power	and	effect	size	was	performed.	
Repeated	measurements	on	single	patients	were	performed	but	it	is	
unclear	if	the	statistical	test	accounted	for	repeated	measures;	
%	ICP	reduction
p	<	0.01
 
hypertonic saline vs. mannitol – RCT 
Group 2 
 
RCT	5
Year 2016 First	Author Jagannatha
Journal JCN
Sample TBI	patients	with	ICP	>	20	mmHg
Treatment 3%	hypertonic	saline	(1027	mOsm/Kg)	2.5	ml/Kg
Control 20%	mannitol	(1160	mOsm/Kg)	2.5	ml/Kg
Outcome %	time	ICP		<	20	mmHg
n°	pz %	time	ICP	<	20	mmHg SD
Treatment 18 63 NA
Control 20 49 NA
Total 38 14 0
Centres 1
Power not	available p	0.3
GRADE	CRITERIA
Allocation	concealment Not	reported
Intention	to	treat	principle	observed Yes
Blinding No
Completement	of	follow-up Yes
Early	stopping No
Bias very	serious
Statistical	reporting	 Partial
Methodological	and	statistical	quality Low
Indirectness No
Publication	bias Not	assessable
Inconsistency	with	other	trials Not	assessable
Size	of	effect Not	assessable
Residual	confounding Not	assessable
Dose	/response Not	investigated
DETAILS
GRADE	rating Low	evidence
Statistical	reporting	 Partial
Methodological	and	statistical	quality Low
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Low	evidence
Outcome
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Bias:	No	blinding	was	performed	although	technically	possible;	
Methodological	and	statistical	quality:	No	sample	size	calculation	
based	on	power	and	effect	size	was	performed.	Very	small	sample	
with	high	chance	of	unbalances	in	important	prognostic	factors	
(measured	and	unmeasured)	between	the	two	study	arms.	
Repeated	measurements	on	single	patients	were	performed	but	it	is	
unclear	if	the	statistical	test	accounted	for	repeated	measures;	
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hypertonic saline vs. mannitol – RCT 
Group 2 
 
RCT	6
Year 2011 First	Author Sakellaridis
Journal JN
Sample TBI	GCS	≤	8	and	ICP	>	20	mmHg
Treatment Hypertonic	saline	15%	(5135	mOsm/Kg)	0.42	ml/Kg
Control 20%	mannitol	(1160	mOsm/Kg)	2	ml/Kg
Outcome Maximum	ICP	reduction
n°	pz mean SD
Treatment 29 7.96 5.8
Control 29 8.43 6.7
Total 29	(crossover) -0.47 0
Centres 1
Power 0.046 p	0.586
GRADE	CRITERIA
Allocation	concealment Not	reported
Intention	to	treat	principle	observed Yes
Blinding No
Completement	of	follow-up Yes
Early	stopping No
Bias very	serious
Statistical	reporting	 Partial
Methodological	and	statistical	quality High
Indirectness No
Publication	bias Not	assessable
Inconsistency	with	other	trials Not	assessable
Size	of	effect Not	assessable
Residual	confounding Not	assessable
Dose	/response Not	investigated
DETAILS
GRADE	rating Low	evidence
Statistical	reporting	 Partial
Methodological	and	statistical	quality High
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Low	evidence
Outcome
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Bias:	The	design	seems	to	resemble	a	cross-over	trial.	No	blinding	
was	performed	although	technically	possible;	Methodological	and	
statistical	quality:	It	is	unclear	how	authors	dealt	with	multiple	
measurements	on	the	same	patient	using	a	paired	t	test	(29	patients	
alternatively	receiving	mannitol	or	HS,	with	199	measures	
performed).	Very	small	sample	with	high	chance	of	unbalances	in	
important	prognostic	factors	(measured	and	unmeasured)	between	
the	two	study	arms.	No	sample	size	calculation	based	on	power	and	
effect	size	was	performed;	
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hypertonic saline vs. mannitol – RCT 
Group 2 
 
 
RCT	7
Year 2011 First	Author Cottenceau
Journal JNT
Sample TBI	GCS	≤	8	and	ICP	>	15	mmHg
Treatment Hypertonic	saline	7.5%
Control 20%	mannitol
Outcome Hospital	mortality
n°	pz mean SD
Treatment 22 5.7 8.2
Control 25 5.8 8.1
Total 47 -0.10
Centres 2
Power 0.027 p	ns
GRADE	CRITERIA
Allocation	concealment Yes
Intention	to	treat	principle	observed Yes
Blinding No
Completement	of	follow-up Yes
Early	stopping Yes
Bias very	serious
Statistical	reporting	
Sufficient	for	quality	
assessment
Methodological	and	statistical	quality Low
Indirectness No
Publication	bias Not	assessable
Inconsistency	with	other	trials Not	assessable
Size	of	effect Not	assessable
Residual	confounding Not	assessable
Dose	/response Not	investigated
DETAILS
GRADE	rating Low	evidence
Statistical	reporting	
Sufficient	for	quality	
assessment
Methodological	and	statistical	quality Low
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Low	evidence
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Bias:	No	blinding	was	performed	although	technically	possible;	
Methodological	and	statistical	quality:	Repeated	measurements	on	
single	patients	were	performed	that	the	authors	seem	to	have	
accounted	for.		No	sample	size	calculation	based	on	power	and	
effect	size	was	performed.	Very	small	sample	with	high	chance	of	
unbalances	in	important	prognostic	factors	(measured	and	
unmeasured)	between	the	two	study	arms;	
 
sodium lactate vs. mannitol - RCT 
Group 2 
 
RCT	1
Year 2009 First	Author Ichai
Journal ICM
Sample TBI	GCS	≤	8	and	ICP	>	25	mmHg	for	>	5	min	
Treatment Sodium	lactate	1100	mosm/kg	1.5	ml/Kg
Control 20%	Mannitol	1160	mosm/kg	1.5	ml/Kg
Outcome ICP	decrease	at	the	fourth	hour
n°	pz ICP	decrease	at	the	fourth	hour
mean SD
Treatment 17 5.9 4.1
Control 17 3.2 3.7
Total 34 2.7
Centres Single	Center
Power 0.492
GRADE	CRITERIA
Allocation	concealment Not	reported
Intention	to	treat	principle	observed Yes
Blinding No
Completement	of	follow-up Yes
Early	stopping No
Bias very	serious
Statistical	reporting	Sufficient	for	quality	assessment
Indirectness No
Imprecision Not	assessable
Publication	bias Not	assessable
Inconsistency	with	other	trials Not	assessable
Size	of	effect Not	assessable
Residual	confounding Not	assessable
Dose	/response Not	investigated
DETAILS
GRADE	rating Low	evidence
Statistical	reporting	
Sufficient	for	quality	
assessment
Methodological	and	statistical	quality Low
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Low	evidence
Outcome
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p	value	0.009
Bias:	No	blinding	was	performed	although	technically	
possible.	It	is	unclear	how	treatment	assignment	was	
concealed	after	envelopes	with	the	5:5	block	randomization	
were	opened;	Methodological	and	statistical	quality:		Small	
sample	with	high	chance	of	unbalances	in	important	
prognostic	factors	(measured	and	unmeasured)	between	the	
two	study	arms.	A	2.7	mmHg	ICP	reduction	although	
statistically	significant	was	not	clinically	meaningful;	
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hypertonic saline in HES vs. mannitol - RCT 
Group 2 
 
RCT	1
Year 1998 First	Author Schwarz
Journal Stroke
Sample Stroke	(mainly	ischemic)
Treatment hypertonic	saline	hydroxyethyl	starch	(osmolarity	2570	mosm/L)	100	ml
Control 20%	mannitol	(1100	mosm/L)	200	ml
Outcome ICP	reduction
n°	pz ICP	reduction
mean SD
Treatment 9 11 na
Control 9 6.4 na
Total 9	(crossover) 4.6 0.0
Centres Single	Center
Power na
GRADE	CRITERIA
Allocation	concealment Not	reported
Intention	to	treat	principle	observed Not	reported
Blinding No
Completement	of	follow-up Yes
Early	stopping No
Bias very	serious
Statistical	reporting	 Partial
Indirectness No
Imprecision Not	assessable
Publication	bias Not	assessable
Inconsistency	with	other	trials Not	assessable
Size	of	effect Not	assessable
Residual	confounding Not	assessable
Dose	/response Not	investigated
DETAILS
GRADE	rating Low	evidence
Statistical	reporting	 Partial
Methodological	and	statistical	quality Low
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Very	low	evidence
Outcome
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p	value	na
Bias:	No	reporting	of	allocation	concealment,	no	blinding	was	
performed	although	technically	possible;	Methodological	and	
statistical	quality:	Repeated	measures	and	crossover	between	
study	groups	were	performed,	but	there	was	neither	a	clear	
crossover	design	nor	a	statistical	approach	that	could	account	
for	repeated	measures.	Very	small	sample	with	high	chance	of	
unbalances	in	important	prognostic	factors	(measured	and	
unmeasured)	between	the	two	study	arms.		No	sample	size	
calculation	based	on	power	and	effect	size	was	performed;	
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hypertonic saline vs. mannitol - observational 
Group 2 
 
 
Observational	study 1 Very	low	evidence		-	Downgraded	study
Year 2015
Journal JN
First	Author Mangat
Statistical	method Optimal	matching
Inclusion	criteria TBI
Treatment Hypertonic	saline	3%
Control Mannitol	20%
Outcome
NA
Centres 22 ICP	reduction:		
N°	patients/centre/year na mean	(SD)
Study	duration	(days) na Treatment:	15.2	(19.9)
Total	(included	in	the	
model)
50 Control:	36.5	(30.9)
Difference:	-21.3:		p	=	0.003
GRADE	CRITERIA
Statistical	reporting	 Sufficient	for	quality	assessment
Methodological	and	statistical	qualityLow
Appropriate	eligibility	criteria Yes
Measurement	of	exposure Yes
Measurement	of	outcome Yes
	Adequate	control	for	
confounding
No
Bias very	serious
GRADE		overall
Size	of	effect Not	relevant
Residual	confounding Does	not	indicate	upgrading
Dose	/response No
DETAILS
D
o
w
n
gr
ad
in
g
U
p
-
gr
ad
in
g
External	validity
GRADE	rating	up/down Downgraded	study
GRADE	rating Very	low	evidence
Statistical	reporting	 Sufficient	for	quality	assessment
Methodological	and	statistical	qualityLow
External	validity	issues Yes
Final	grading Downgraded	study
Final	level	of	evidence Very	low	evidence
Sufficient	number	of	centers	but	on	average	only	about	2	patients	for	centers	were	enrolled	in	the	study
U
p
-
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g
	Adequate	control	for	confounding:	Few	important	clinical	variables	selected	for	matching	(initial	GCS,	
hypotension,	pupil	reactivity,	surgical	lesion).	Methodological	and	statistical	quality:	The	study	does	not	account	
sufficiently	for	confounding.	
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Conclusive	evaluation	
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query and body of evidence grading 
 
Group 2 
SG2 Q3: Efficacy: is there evidence supporting osmotic drugs use in patients with 
intracranial pathologies but without ICP monitoring? 
 
 
Studies were too heterogeneous to be combined in an overall body of evidence. Their 
individual grading (reported in the quality assessment forms at the end of this 
document) hence corresponds to the body of evidence grading.  
 
We retrieved only two small RCTs bearing serious methodological limitations. One RCT 
randomized to 20% mannitol or 23.4% HS 9 patients, measuring one hour after 
administration cerebral blood flow (CBF), blood volume (CBV), oxygen extraction 
fraction (OEF), and oxygen metabolism (CMRO2) [1]. No significant differences were 
found. The second RCT compared 20% mannitol and the same volume of normal 
saline, in patients with supratentorial intracerebral hemorrhage and midline shift of 
at least 3 mm. No differences in shift reduction were found [2]. In both studies no 
preliminary sample size calculation was performed, and the study were clearly 
underpowered and unable to show and clinically meaningful difference. Evidence 
provided by both studies was downgraded to very low. 
 
Other selected studies were observational, investigating very small samples, without 
any adjustment for confounders and are briefly described below. No detailed grading 
form was filled for these studies. Differently from Q1, where numerous studies were 
sufficiently homogenous in terms of treatment and outcome, the high heterogeneity 
hampers the finding of a common pathophysiological base and advises against 
combination of results. Evidence provided by these studies was graded as very low. 
 
Available studies investigated mostly alternative monitoring strategies to assess 
mannitol effect. No evidence was found concerning mannitol administration in the 
presence of clinical changes without ICP monitoring. 
Only one study investigating EEG modifications after mannitol administration in stroke 
patients performed a multivariable analysis on 37 hemorrhagic stroke.[3] The 
 
query and body of evidence grading 
 
Group 2 
reporting of statistics was partial and confused, and results were not clearly 
illustrated. Aside from these shortcomings, the model was clearly overfitted, with 7 
variables tested in the model. 
Most studies focused the effects of mannitol or hypertonic saline on cerebral 
hemodynamics in patients with spontaneous intracerebral hemorrhage or TBI, 
measured with transcranial doppler,[4-6] positron emission tomography,[7, 8] Xenon-
133 inhalation method.[9, 10] Other studies considered brain volume and shift, or its 
water content.[11-15]  
Another interesting study reported the differential effect of hypertonic saline bolus 
on the volume of contused (increased) and non-contused cerebral (decreased) areas 
by CT scan measurements.[13] Unfortunately the study was carried out on 14 patients 
only and cold not provide robust evidence, although generating an important 
hypothesis. 
Several other studies evaluated cerebral blood flow changes after osmotic therapy 
was administered. 
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mannitol vs. normal saline (outcome shift reduction at MRI) 
Group 2 
 
RCT	1
Year 2007 First	Author Misra
Journal EJN
Sample Intracerebral	hemorrhage	with	shift	≥	3	mm
Treatment 20%	mannitol	1.5	gr/Kg	2	ml/Kg
Control 0.9%	saline		2	ml/Kg
Outcome Shift	reduction	at	MRI
n°	pz N	episodes/day
mean SD
Treatment 12 6.8 2.2
Control 12 6.6 2.2
Total 24 0.2 0.0
Centres Single	Center
Power 0.039
GRADE	CRITERIA
Allocation	concealment Not	reported
Intention	to	treat	principle	observed Not	reported
Blinding No
Completement	of	follow-up Yes
Early	stopping No
Bias very	serious
Statistical	reporting	 Partial
Indirectness No
Imprecision Not	assessable
Publication	bias Not	assessable
Inconsistency	with	other	trials Not	assessable
Size	of	effect Not	assessable
Residual	confounding Not	assessable
Dose	/response Not	investigated
DETAILS
GRADE	rating Very	low	evidence
Statistical	reporting	 Partial
Methodological	and	statistical	quality Low
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Very	low	evidence
Bias:	No	reporting	of	allocation	concealment,	no	blinding	was	
performed	although	technically	possible;	Methodological	and	
statistical	quality:	Very	small	sample	with	high	chance	of	
unbalances	in	important	prognostic	factors	(measured	and	
unmeasured)	between	the	two	study	arms.		No	sample	size	
calculation	based	on	power	and	effect	size	was	performed.	
The	study	was	underpowered	to	detect	any	realistic	effect;	
Imprecision:	Although	not	measurable;	
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query and body of evidence grading 
Group 2 
 
 
 
 
 
query and body of evidence grading 
Group 2 
 
 
SG2 Q4: Efficacy: is there evidence that osmotic therapies used in TBI (or other 
intracranial pathologies) improve outcome? 
 
Three trials and three observational studies were graded. 
The trials were heterogeneous in terms of design and could not be combined in a 
meta-analysis [1-3]. Their individual grading (reported in the quality assessment forms 
at the end of this document) hence corresponds to the body of evidence grading. The 
first RCT compared sodium lactate vs. normal saline infusion for the prevention of ICP 
increases over 20 mmHg in TBI in the first 48 hours from admission. The study showed 
a statistically significant reduction of the number of such episodes but no 
improvement in the 6-months neurologic outcome (two form are reported below, one 
for the surrogate and one for the robust outcome). The second RCT could not 
demonstrate the superiority of sodium lactate on mannitol in TBI patients in terms of 
long-term neurologic outcome. The third RCT did not show any beneficial effect of HS 
on ringer lactate. 
The three observational studies dealt with TBI, SAH, and intracerebral hemorrhage. 
The first two were downgraded for methodological biases [4, 5]. The third was of high 
quality according to the GRADE classification and to our final evaluation [6]. 
 
 
 
Sodium lactate vs. saline – RCT 
 
Group 2 
RCT	4
Year 2013 First	Author Ichai
Journal ICM
Sample TBI	GCS	≤	8	
Treatment Sodium	lactate	infusion
Control 0.9%	saline	infusion
Outcome n	of	ICP	<	20	mmHg	episodes
n°	pz n %
Treatment 30 11 36.7
Control 30 20 66.7
Total 60 31 51.66666667
Centres 2
Power 0.683
GRADE	CRITERIA
Allocation	concealment Yes
Intention	to	treat	principle	observed Yes
Blinding Yes
Completement	of	follow-up Yes
Early	stopping No
Statistical	reporting	 Sufficient	for	quality	assessment
Methodological	and	statistical	quality Low
Indirectness No
Publication	bias No
Inconsistency	with	other	trials Not	assessable
Size	of	effect Not	relevant
Residual	confounding Not	assessable
Dose	/response Not	relevant
DETAILS
GRADE	rating Moderate	evidence
Statistical	reporting	 Sufficient	for	quality	assessment
Methodological	and	statistical	quality Low
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Low	evidence
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Methodological	and	statistical	quality:	Small	sample	with	high	chance	of	
unbalances	in	important	prognostic	factors	(measured	and	unmeasured)	
between	the	two	study	arms	and	a	high	risk	of	overoptimistic	estimates;	
Imprecision:	Confidence	interval	includes	a	wide	range	of	possibilities	from	
strongly	protective	to	strongly	detrimental	effects.	Power	was	very	low	in	
relation	to	the	measured	effect;	
NNTB	3	(95%-CI	NNTB	2	to	NNTB	21)
delta	-30	(95%-CI	-50.4	to	-4.8)
 
Sodium lactate vs. saline – RCT 
 
Group 2 
RCT	1
Year 2013 First	Author Ichai
Journal ICM
Sample TBI	GCS	≤	8	
Treatment Sodium	lactate	infusion
Control 0.9%	saline	infusion
Outcome 6-months	GOS	(poor	outcome)
n°	pz n %
Treatment 30 12 40.0
Control 30 15 50.0
Total 60 27 45.0
Centres 2	Centres
Power 0.119
GRADE	CRITERIA
Allocation	concealment Yes
Intention	to	treat	principle	observed Yes
Blinding Yes
Completement	of	follow-up Yes
Early	stopping No
Bias No
Statistical	reporting	
Sufficient	for	quality	
assessment
Indirectness No
Imprecision very	serious
Publication	bias Not	assessable
Inconsistency	with	other	trials Not	assessable
Size	of	effect Not	relevant
Residual	confounding Not	assessable
Dose	/response Not	relevant
DETAILS
GRADE	rating Moderate	evidence
Statistical	reporting	
Sufficient	for	quality	
assessment
Methodological	and	statistical	quality Low
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Low	evidence
Methodological	and	statistical	quality:	Small	sample	with	high	
chance	of	unbalances	in	important	prognostic	factors	
(measured	and	unmeasured)	between	the	two	study	arms	
and	a	high	risk	of	overoptimistic	estimates;	Imprecision:	
Confidence	interval	includes	a	wide	range	of	possibilities	from	
strongly	protective	to	strongly	detrimental	effects.	Power	was	
very	low	in	relation	to	the	measured	effect;	
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Outcome
NNTB	10	(95%-CI	NNTB	3	to	∞	to	NNTH	7)
delta	-10	(95%-CI	-32.8	to	14.4)
 
Sodium lactate vs. mannitol – RCT 
 
Group 2 
RCT	2
Year 2009 First	Author Ichai
Journal ICM
Sample TBI	GCS	≤	8	and	ICP	>	25	mmHg	for	>	5	min	
Treatment Sodium	lactate
Control 20%	Mannitol
Outcome 12-months	GOS	(poor	outcome)
n°	pz n %
Treatment 17 6 35.3
Control 16 11 68.8
Total 33 17 51.5
Centres Single	Center
Power 0.532
GRADE	CRITERIA
Allocation	concealment No
Intention	to	treat	principle	observed Yes
Blinding No
Completement	of	follow-up Yes
Early	stopping No
Bias serious
Statistical	reporting	 Sufficient	for	quality	assessment
Methodological	and	statistical	quality Low
Indirectness No
Publication	bias No
Inconsistency	with	other	trials Not	assessable
Size	of	effect Not	relevant
Residual	confounding Not	assessable
Dose	/response Not	relevant
DETAILS
GRADE	rating Low	evidence
Statistical	reporting	 Sufficient	for	quality	assessment
Methodological	and	statistical	quality Low
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Low	evidence
Bias:	No	blinding	was	performed	although	technically	possible.	It	is	
unclear	how	treatment	assignment	was	concealed	after	envelopes	with	
the	5:5	block	randomization	were	opened;	Methodological	and	statistical	
quality:	Small	sample	with	high	chance	of	unbalances	in	important	
prognostic	factors	(measured	and	unmeasured)	between	the	two	study	
arms.	The	effect	size	was	very	large	with	a	high	risk	of	overestimation,	
particularly	relevant	when	combined	with	a	high	degree	of	imprecision;	
Imprecision:	Wide	confidence	interval	with	a	high	degree	of	uncertainty;	D
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Outcome
NNTB	3	(95%-CI	NNTB	2	to	∞	to	NNTH	316)
delta	-33.5	(95%-CI	-58.3	to	0.3)
 
hypertonic saline vs. ringer lactate - RCT 
Group 2 
 
 
RCT	3
Year 2004 First	Author Cooper
Journal JAMA
Sample TBI	GCS	≤	8	and	SAP	<	100	mmHg
Treatment Prehospital	250	ml	hypertonic	saline	7.5%
Control Prehospital	250	ml	ringer	lactate
Outcome 6-month	GOSE
n°	pz 6-month	GOSE	score
median IQR
Treatment 113 5 (3-6)
Control 113 5 (5-6)
Total 226 0 0.0
Centres 12	Centres
Power not	available
GRADE	CRITERIA
Allocation	concealment Yes
Intention	to	treat	principle	observed Yes
Blinding Yes
Completement	of	follow-up Yes
Early	stopping No
Bias No
Statistical	reporting	
Sufficient	for	quality	
assessment
Indirectness No
Imprecision No
Publication	bias Not	assessable
Inconsistency	with	other	trials Not	assessable
Size	of	effect Not	assessable
Residual	confounding Not	assessable
Dose	/response Not	investigated
DETAILS
GRADE	rating High	evidence
Statistical	reporting	
Sufficient	for	quality	
assessment
Methodological	and	statistical	quality High
External	validity	issues No
Final	grading No	grading	modification
Final	level	of	evidence High	evidence
Outcome
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hypertonic saline - OBS 
Group 2 
 
 
 
 
 
Observational	study 1 Very	low	evidence		-	Downgraded	study
Year 1997
Journal JT
First	Author Wade
Statistical	method Logistic	regression
Inclusion	criteria AIS	for	head	region	≥	4
Treatment Prehospital	hypertonic	saline	7.5%/dextran-70	250	ml
Outcome
Hospital		mortality:	33	(19.9%)
Centres NA Variable:	OR	(95%-CI)
N°	patients/centre/year NA Hypertonic	saline	yes/no:	2.12	(1.01-4.49)
Study	duration	(days) NA
Total	(included	in	the	
model)
166
GRADE	CRITERIA
Statistical	reporting	 Partial
Statistical	quality Low
Appropriate	eligibility	criteria Yes
Measurement	of	exposure Yes
Measurement	of	outcome Yes
	Adequate	control	for	
confounding
No
Bias very	serious
GRADE		overall
Size	of	effect Large
Residual	confounding Does	not	indicate	upgrading
Dose	/response Not	applicable
DETAILS
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External	validity
GRADE	rating	up/down Downgraded	study
GRADE	rating Very	low	evidence
Statistical	reporting	 Partial
Statistical	quality Low
External	validity	issues No
Final	grading Downgraded	study
Final	level	of	evidence Very	low	evidence
No	external	validity	issues
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Size	of	effect:	The	result	of	a	biased	analysis.	To	not	indicate	upgrading.	
Statistical	reporting	:	The	reporting	of	multivariable	results	is	insufficient	to	uderstand	how	the	model	was	
developed	in	detail.	Statistical	quality:	The	logistic	regression	model	has	explanatory	pruposes	but	it	includes	
few	variables	for	mortality	prediction	(probable	underfitting).	On	the	other	hand	the	study	runs	a	high	risk	of	
bening	overfitted	since	5	variables	entered	the	model	with	only	33	events	available	(ratio	events/variables	<	
10/1).	Finally,	although	investigating	a	treatment		a	propensity	score	is	not	applied	to	account	for	selection	bias.	
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Conclusive	evaluation	
 
mannitol - OBS 
Group 2 
 
Observational	study 2 Very	low	evidence		-	Downgraded	study
Year 2003
Journal Stroke
First	Author Bereczki
Statistical	method Logistic	regression
Inclusion	criteria
Treatment Mannitol	(dose	and	timing	not	specified)
Outcome
1-year	mortality:	35	(6.5%)
Centres 3 Variable:	OR	(95%-CI)
N°	patients/centre/year 180 Mannitol	yes/no:	0.53	(0.36-0.79)
Study	duration	(days) 365
Total	(included	in	the	
model)
540
GRADE	CRITERIA
Statistical	reporting Partial
Statistical	quality Low
Appropriate	eligibility	criteria Yes
Measurement	of	exposure Yes
Measurement	of	outcome Yes
	Adequate	control	for	
confounding
No
Bias serious
GRADE		overall
Size	of	effect Not	relevant
Residual	confounding Does	not	indicate	upgrading
Dose	/response Not	applicable
DETAILS
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External	validity
GRADE	rating	up/down Downgraded	study
GRADE	rating Very	low	evidence
Statistical	reporting Partial
Statistical	quality Low
External	validity	issues Yes
Final	grading Downgraded	study
Final	level	of	evidence Very	low	evidence
SAH	patients
U
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Measurement	of	outcome:	A	combined	outcome	including	severe	disability	besides	mortality	is	to	be	preferred	to	
mortality	alone	when	dealing	with	long-term	neurologic	outcome.	Statistical	quality:	Although	dealing	with	a	
treatment	no	propensity	score	was	developed	to	account	for	selection	bias.	Heterogeneous	findings	concerning	
mannitol	effectiveness	were	provided	by	different	models,	which	appeared	to	be	underfitted	to	explain	mortality.	
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No	external	validity	issues
Conclusive	evaluation	
 
mannitol - OBS 
Group 2 
 
Observational 3 Low	evidence		-	No	grading	modification
Year 2015
Journal Stroke
First	Author Wang
Statistical	method Logistic	regression	with	propensity	score	adjustment
Inclusion	criteria
Treatment mannitol	within	7	days	from	admission,	dose	not	defined
Outcome
Rankin	scale	3-6	at	90	days:	1341	(53.1%)
Centres NA Variable:	OR	(95%-CI)
N°	patients/centre/year NA Mannitol	yes/no:	1.02	(0.81-1.30)
Study	duration	(days) NA
Total	(included	in	the	
model)
2526
GRADE	CRITERIA
Statistical	reporting Sufficient	for	quality	assessment
Statistical	quality High
Appropriate	eligibility	criteria Yes
Measurement	of	exposure Yes
Measurement	of	outcome Yes
	Adequate	control	for	
confounding
Yes
Bias No
GRADE		overall
Size	of	effect Not	relevant
Residual	confounding Does	not	indicate	upgrading
Dose	/response Not	applicable
DETAILS
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External	validity
GRADE	rating	up/down No	grading	modification
GRADE	rating Low	evidence
Statistical	reporting Sufficient	for	quality	assessment
Statistical	quality High
External	validity	issues No
Final	grading No	grading	modification
Final	level	of	evidence Low	evidence
Conclusive	evaluation	
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No	external	validity	issues
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Acute	cerebral	hemorrhage
 
query and body of evidence grading (SAH) 
 
Group 3 
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SG3 Q1 Is there enough evidence to prefer specific fluids (crystalloids/colloids) in 
the prevention of cerebral ischemia (CBF or clinical) in patients with stroke 
(subarachnoid hemorrhage)? 
 
 
Studies were too heterogeneous to be combined in an overall body of evidence. Their 
individual grading (reported in the quality assessment forms at the end of this 
document) hence corresponds to the body of evidence grading.  
 
 
query and body of evidence grading (SAH) 
 
Group 3 
We considered studies focused on the prevention of new ischemic events, i.e. 
vasospasm and its consequences, in subarachnoid haemorrhage (SAH). 
We found two small randomized controlled clinical trials (RCTs), one adopting a triple 
H protocol for the treatment arm, and for this reason a confounding effect of 
hypertensive therapy could not be ruled out [1]. The study could not demonstrate any 
differences in terms of occurrence of vasospasm, of regional cerebral blood flow 
(CBF), and of one-year GOS. The other study compared hypervolemic and 
normovolemic approaches based on hemodynamic parameters [2]. The study did not 
show either any improvement of regional and global CBF, or differences in the 
frequency of vasospasm and cerebral infarction. The two RCTs were small and 
consequently prone to several biases. 
A third RCT was not included in our analysis because it combined multiple 
interventions (including volume expansion) for the prevention of vasospasm, thus not 
providing reliable information of single elements of the therapeutic approach [3].  
We also found several observational studies that were so heterogeneous in terms of 
treatment protocols and outcomes that it was not possible to combine in a single body 
of evidence. We made a detailed reporting of our grading process only for studies 
using statistical techniques to adjust for confounding, while graded the others as very 
low quality. 
Among studies not performing statistical adjustment for confounders we report six 
with a before-after design that appeared more interesting than others in terms of 
hypothesis generation. However, results appeared to be conflicting although 
differences in treatment and study design could explain inconsistencies. The studies 
we carried out in few patients and in single centres that raises external validity issues. 
One study investigated an hypervolemic approach reporting an increase in regional 
CBF dissociated from any significant variation of cerebral oxygenation (PbtO2) [4]. In 
a second study, hypertonic saline infusion in fourteen patients was associated with 
PbO2 increase [5]. Volume expansion with albumin and hypertonic saline was 
associated with CBF reduction and increase, respectively [6-8], while it remained 
unchanged when normal saline was used [9]. 
 
query and body of evidence grading (SAH) 
 
Group 3 
Among studies carrying out statistical adjustment for confounders we excluded one 
that used a combined outcome including delayed cerebral ischemia (DCI), 
hydrocephalus, and rebleeding, because it did not provide specific information on the 
outcome of interest [10]. Among the other six observational studies retrieved that 
used a multivariable approach, only two investigated DCI specifically [11, 12]. The 
other studies investigated mortality or long-term neurologic outcome [13-16], and are 
thus of interest also for SG1. 
 
Hypervolemia vs. Normovolemia - RCT 
Group 3 
 
 
 
RCT	1
Year 2001 First	Author Egge
Journal Neurosurgery
Sample aSAH	patients
Treatment
Control
Outcome vasospasm	(TDS	+	Lindegaard	index)
n°	pz n %
Treatment 16 4 25.0
Control 16 5 31.3
Total 32 9 28.1
Centres 2	Centres
Power 0.059
GRADE	CRITERIA
Allocation	concealment Not	reported
Intention	to	treat	principle	observed Not	reported
Blinding No
Completement	of	follow-up Yes
Early	stopping No
Bias No
Statistical	reporting	
Sufficient	for	quality	
assessment
Indirectness No
Imprecision very	serious
Publication	bias Not	assessable
Inconsistency	with	other	trials Not	assessable
Size	of	effect Not	relevant
Residual	confounding Not	assessable
Dose	/response Not	relevant
DETAILS
GRADE	rating Low	evidence
Statistical	reporting	
Sufficient	for	quality	
assessment
Methodological	and	statistical	quality Low
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Very	low	evidence
Outcome
NNTB	16	(95%-CI	NNTB	3	to	∞	to	NNTH	4)
delta	-6.3	(95%-CI	-34.8	to	23.6)
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Methodological	and	statistical	quality:	Small	sample	with	high	
chance	of	unbalances	in	important	prognostic	factors	
(measured	and	unmeasured)	between	the	two	study	arms	and	
a	high	risk	of	overoptimistic	estimates;	
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Triple-H	treatment	:2L	saline-	2L	5%-500-1000	ml	collids	(albumin	o	
rheomacrodex)	dextrose/day
No	triple-H	treatment	:1L	saline-	1L	5%	dextrose/day
 
Hypervolemia vs. Normovolemia - RCT 
Group 3 
 
 
 
 
RCT	2
Year 2000 First	Author Lennihan
Journal Stroke
Sample SAH	patients	with	clipped	aneurysm
Treatment PADP	≥	14	or	CVP	≥	8	mmHg	
Control PADP	≥	7	or	CVP	≥	5	mmHg	
Outcome symptomatic	vasospasm
n°	pz n %
Treatment 41 8 19.5
Control 41 8 19.5
Total 82 16 19.5
Centres Single	Center
Power 0.025
GRADE	CRITERIA
Allocation	concealment No
Intention	to	treat	principle	observed Yes
Blinding No
Completement	of	follow-up Yes
Early	stopping No
Bias very	serious
Statistical	reporting	 Sufficient	for	quality	assessment
Methodological	and	statistical	quality Low
Indirectness No
Publication	bias No
Inconsistency	with	other	trials Not	assessable
Size	of	effect Not	relevant
Residual	confounding Not	assessable
Dose	/response Not	relevant
DETAILS
GRADE	rating Low	evidence
Statistical	reporting	 Sufficient	for	quality	assessment
Methodological	and	statistical	quality Low
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Very	low	evidence
Outcome
NNTB/	NNTH	∞	(95%-CI	NNTB	6	to	∞	to	NNTH	6)
delta	0	(95%-CI	-17.2	to	17.2)
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Bias:	No	blinding	or	allocation	concelament	were	performed	although	
technically	possible.;	Methodological	and	statistical	quality:	Small	sample	
with	high	chance	of	unbalances	in	important	prognostic	factors	
(measured	and	unmeasured)	between	the	two	study	arms;	Imprecision:	
Wide	confidence	interval	with	a	high	degree	of	uncertainty;	
 
Hypervolemia vs. Normovolemia - RCT 
Group 3 
 
 
 
RCT	3
Year 2000 First	Author Lennihan
Journal Stroke
Sample SAH	patients	with	clipped	aneurysm
Treatment PADP	≥	14	or	CVP	≥	8	mmHg	
Control PADP	≥	7	or	CVP	≥	5	mmHg	
Outcome Cerebral	infarction
n°	pz n %
Treatment 41 7 17.1
Control 41 4 9.8
Total 82 11 13.4
Centres 1
Power 0.163
GRADE	CRITERIA
Allocation	concealment No
Intention	to	treat	principle	observed Yes
Blinding No
Completement	of	follow-up Yes
Early	stopping No
Bias No
Statistical	reporting	
Sufficient	for	quality	
assessment
Methodological	and	statistical	quality High
Indirectness No
Publication	bias No
Inconsistency	with	other	trials Not	assessable
Size	of	effect Not	relevant
Residual	confounding Not	assessable
Dose	/response Not	relevant
DETAILS
GRADE	rating Low	evidence
Statistical	reporting	
Sufficient	for	quality	
assessment
Methodological	and	statistical	quality High
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Very	low	evidence
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NNTH	14	(95%-CI	NNTB	12	to	∞	to	NNTH	4)
Outcome
delta	7.3	(95%-CI	-8.1	to	22.7)
 
Different fluid administration approaches – OBS 
 
Group 3 
 
 
 
Observational	study 1
Year 2013
Journal JN
First	Author Kuwabara
Statistical	method Logistic	regression	with	propensity	score	adjustment
Inclusion	criteria SAH
treatment Albumin
control no	albumin Outcome
Hospital		mortality
Centres NA Variable:	OR	(95%-CI)
N°	patients/centre/year NA Albumin	g/kg/day	(continuous)	Pre-DCI:	4.39	(0.9-21.37)
Study	duration	(days) NA Albumin	g/kg/day	(continuous)	DCI:	2.55	(0.29-22.65)
Total	(included	in	the	
model)
5400
GRADING	CRITERIA
Statistical	reporting	 Partial
Methodological	and	statistical	qualityLow
Appropriate	eligibility	criteria Yes
Measurement	of	exposure Yes
Measurement	of	outcome Yes
	Adequate	control	for	
confounding
No
Bias very	serious
Size	of	effect Large
Residual	confounding Does	not	indicate	upgrading
Dose	/response No
DETAILS
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External	validity
GRADE	rating	up/down Downgrading
GRADE	rating Very	low	evidence
Statistical	reporting	 Partial
Methodological	and	statistical	qualityLow
External	validity	issues No
Final	grading Downgrading
Final	level	of	evidence Very	low	evidence
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Size	of	effect:	Large	non	statistically	significant	effect	with	high	level	of	imprecision.	
	Adequate	control	for	confounding:	Data	from	administrative	database.	Few	important	clinical	variables	
included	in	the	model.	Statistical	reporting	:	The	reporting	of	multivariable	results	is	insufficient	to	uderstand	
how	the	model	was	developed	in	detail.	There	is	insufficient	information	on	the	variable		selection	procedure.	
Methodological	and	statistical	quality:	It	seems	that	DCI	diagnosis	was	attributed	on	the	basis	of	the	number	of	
days	from	admission,	individuating	a	pre-DCI	and	a	DCI	period,	and	not	on	the	basis	of	a	clinical/instrumental	
diagnosis.	The	definition	of	these	periods	was	crucial	in	the	development	of	the	model	that	was	prone	to	
misleading	interpretations.	
Conclusive	evaluation	
 
Different fluid administration approaches – OBS 
 
Group 3 
 
 
Observational	study 2
Year 2004
Journal JN
First	Author Suarez
Statistical	method Logistic	regression
Inclusion	criteria
treatment Albumin
control no	albumin Outcome
GOS	≥	4:	43	(51.2%)
Centres 1 Variable:	OR	(95%-CI)
N°	patients/centre/year 42 Albumin:	3.2	(1.1-11.0)
Study	duration	(days) 731
Total	(included	in	the	
model)
84
GOS	≥	4 43	(51.2%)
GRADING	CRITERIA
Statistical	reporting Partial
Statistical	quality Low
Appropriate	eligibility	criteria Yes
Measurement	of	exposure Yes
Measurement	of	outcome Yes
	Adequate	control	for	
confounding
No
Bias very	serious
Size	of	effect Large
Residual	confounding Does	not	indicate	upgrading
Dose	/response Not	applicable
DETAILS
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External	validity
GRADE	rating	up/down Downgrading
GRADE	rating Very	low	evidence
Statistical	reporting	 Partial
Methodological	and	statistical	qualityLow
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Very	low	evidence
Conclusive	evaluation	
Single	center	study
SAH
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	Adequate	control	for	confounding:	Important	predictors	were	not	included	in	logistic	regression	(only	age,	sex,	
race,	and	treatment	entered	the	model)..	Statistical	reporting	:	Insufficient	information	on	how	the	model	was	
developed	(e.g.	variable	selection,	management	of	continuous	variables)	were	provided.	No	information	on	the	fit	
of	the	model	was	available..	Methodological	and	statistical	quality:	The	small	sample	size	hampered	the	
development	of	a	multivariable	approach	with	explanatory	purposes.	The	model	was	underfitted	but	it	could	not	
include	more	variables	because	of	the	risk	of	overfitting.	No	propensity	score	was	developed..	
Size	of	effect:	Large	protective	effect	generated,	however,	by	a	potentially	biased	model.	No	upgrading	indicated.	
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Different fluid administration approaches – OBS 
 
Group 3 
 
 
Observational 3
Year 2015
Journal JSCD
First	Author Kissoon
Statistical	method Logistic	regression	with	propensity	score	adjustment
Inclusion	criteria
treatment Positive	fluid	balance
control Even	fluid	balance Outcome
DCI:	190	(66%)
Centres 1 Variable:	HR	(95%-CI)
N°	patients/centre/year 28 Positive	fluid	balance:	1.18	(1.08-1.29)
Study	duration	(days) 3803
Total	(included	in	the	
model)
288
GRADING	CRITERIA
Statistical	reporting Partial
Statistical	quality Low
Appropriate	eligibility	criteria Yes
Measurement	of	exposure Yes
Measurement	of	outcome Yes
	Adequate	control	for	confounding No
Bias very	serious
Size	of	effect Not	relevant
Residual	confounding Does	not	indicate	upgrading
Dose	/response Yes
DETAILS
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External	validity
GRADE	rating	up/down Downgrading
GRADE	rating Very	low	evidence
Statistical	reporting	 Partial
Methodological	and	statistical	quality Low
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Very	low	evidence
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SAH
	Adequate	control	for	confounding:		Only	5	variables	selected	in	the	model,	an	insufficient	number	for	explanatory	
purposes.	Statistical	reporting	:	Insufficient	information	on	how	the	model	was	developed	(e.g.	variable	selection,	
management	of	continuous	variables)	were	provided.	No	information	on	the	fit	of	the	model	was	available..	
Methodological	and	statistical	quality:	The	model	was	underfitted	given	its	explanatory	purposes.	
Dose	/response:	The	model	was	too	weak	to	take	in	account	the	positive	dose/response	relation.	
Single	center	study
Conclusive	evaluation	
 
Different fluid administration approaches – OBS 
 
Group 3 
 
 
Observational	study 4
Year 2012
Journal NC
First	Author Martini
Statistical	method Cox	proportional	hazards
Inclusion	criteria
treatment Positive	fluid	balance	after	the	first	3	days
control Negative	fluid	balance	after	the	first	3	daysOutcome
Hospital	mortality	or	new	stroke:	117	(32.9%)
Centres 1 Variable:	HR	(95%-CI)
N°	patients/centre/year 63 3-day	positive	fluid	balance:	1.47	(0.85-2.54)
Study	duration	(days) 2071
Total	(included	in	the	
model)
356
GRADING	CRITERIA
Statistical	reporting Partial
Statistical	quality Low
Appropriate	eligibility	criteria Yes
Measurement	of	exposure Yes
Measurement	of	outcome Yes
	Adequate	control	for	confounding No
Bias very	serious
Size	of	effect Not	relevant
Residual	confounding Does	not	indicate	upgrading
Dose	/response Yes
DETAILS
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External	validity
GRADE	rating	up/down No	grading	modification
GRADE	rating Low	evidence
Statistical	reporting	 Partial
Methodological	and	statistical	qualityLow
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Very	low	evidence
Single	center	study.
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	Adequate	control	for	confounding:		Insufficient	number	of	variables	for	an	explanatory	model.	Statistical	reporting	:	
Insufficient	information	on	how	the	model	was	developed	(e.g.	variable	selection,	management	of	continuous	
variables)	were	provided.	Methodological	and	statistical	quality:	The	model	was	underfitted.	No	propensity	score	
was	developed.	
SAH	patients
Conclusive	evaluation	
 
Different fluid administration approaches – OBS 
 
Group 3 
  
 
Observational	study 5
Year 2013
Journal NC
First	Author Ibrahim
Statistical	method Case-control	with	mactching
Inclusion	criteria
treatment Colloids	administration
control No	colloids Outcome
DCI:	delta	3.7	(95%-CI	-14.5	to	21.6)
Centres 1 DCI:	NNTH	27	(95%-CI	NNTB	7	to	∞	to	NNTH	5)
N°	patients/centre/year 106 p	=	0.71
Study	duration	(days) 424
Total	(included	in	the	
model)
123
GRADING	CRITERIA
Statistical	reporting Sufficient	for	quality	assessment
Statistical	quality High
Appropriate	eligibility	criteria Yes
Measurement	of	exposure Yes
Measurement	of	outcome Yes
	Adequate	control	for	
confounding
No
Bias very	serious
Size	of	effect
Residual	confounding Does	not	indicate	upgrading
Dose	/response No
DETAILS
D
o
w
n
gr
ad
in
g
U
p
-
gr
ad
in
g
External	validity
GRADE	rating	up/down Downgrading
GRADE	rating Very	low	evidence
Statistical	reporting	 Sufficient	for	quality	assessment
Methodological	and	statistical	qualityHigh
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Very	low	evidence
Conclusive	evaluation	
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	Adequate	control	for	confounding:	Important	predictors	were	not	included	in	the	propensity	score.	
SAH
Single	center	study
 
Different fluid administration approaches – OBS 
 
Group 3 
 
 
Observational 6
Year 2014
Journal NC
First	Author Tagami
Statistical	method Cox	proportional	hazards
Inclusion	criteria
treatment Tripple	H
control No	tripple	H Outcome
Hospital	mortality:	35	(19.7%)
Centres 9 Variable:	HR	(95%-CI)
N°	patients/centre/year 6 Tripple	H:	1.27	(0.62-2.62)
Study	duration	(days) 1247
Total	(included	in	the	
model)
178
GRADING	CRITERIA
Statistical	reporting Partial
Statistical	quality Low
Appropriate	eligibility	criteria Yes
Measurement	of	exposure Yes
Measurement	of	outcome Yes
	Adequate	control	for	
confounding
No
Bias very	serious
Size	of	effect Not	relevant
Residual	confounding Does	not	indicate	upgrading
Dose	/response Not	applicable
DETAILS
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External	validity
GRADE	rating	up/down Downgrading
GRADE	rating Very	low	evidence
Statistical	reporting	 Partial
Methodological	and	statistical	qualityLow
External	validity	issues No
Final	grading Downgrading
Final	level	of	evidence Very	low	evidence
Multicenter	study,	with	an	acceptable	number	of	patients	treated	per	center.
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	Adequate	control	for	confounding:	Only	five	variables	remained	in	the	final	model,	insufficient	number	for	
explanatory	purposes.	No	propensity	score	included	in	the	model.	Statistical	reporting	:	No	mention	of	the	
variable	selection	method.	No	detailed	statistical	reporting.	Methodological	and	statistical	quality:	Hazard	
proportional	assumption	not	checked.	Few	variables	entered	the	prediction	model.	
SAH
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Conclusive	evaluation	
 
query and body of evidence grading (SAH) 
 
Group 3 
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SG3 Q2 Does fluid therapy in the management of cerebral ischemia influence 
outcome (CBF or clinical)? 
 
Studies were too heterogeneous to be combined in an overall body of evidence. Their 
individual grading (reported in the quality assessment forms at the end of this 
document) hence corresponds to the body of evidence grading.  
 
We only retrieved observational studies, which did not perform any statistical 
adjustment for confounders. Studies were small and those with a before-after design 
that may provide some interesting information were too heterogeneous in terms of 
design to be combined with a meta-analytical approach. Moreover, studies did not 
always provide consistent findings. We briefly summarise some of these studies that, 
at the best, may only provide hypotheses. 
Normal saline bolus in six patients with vasospasm determined a significant CBF 
increase in areas with low perfusion [1]. In 35 patients with vasospasm receiving 
hypertonic saline boluses also experienced an increase of CBF [2]. Finally, 
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hypervolemia obtained with albumin, low-molecular-weight dextran, and 10% glicerol 
was associated with normalization of CBF in the cerebral emisphere where it was 
reduced by vasospasm [3]. 
In two studies volemia expansion with hetastarch and albumin, or isovolemic 
hemodilution obtained by venisection and infusion of albumin and dextran 70, 
respectively,  did not increase CBF [4, 5]. 
Two studies treated new neurological symptoms in SAH with hypervolemia using 
albumin, glicerol, dextran, or plasma, monitoring part of these patients with a Swan-
Ganz catheter. Neurologic improvement and absence of progression to infarction in 
most cases led the authors to conclude that hypervolemic therapy was effective [6, 
7]. The two studies, however, had very serious limitations connected to the small 
sample size, to the absence of a instrumental diagnosis of vasospasm, no specific 
definition of teatment, and lack of adjustment for confounding factor. 
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SG3 Q3 Is there enough evidence to prefer specific fluids (cristalloids/colloids) in 
the management of cerebral ischemia for CBF augmentation/clinical outcome? 
 
We retrieved only one observational study that considered long-term outcome that 
was not the kind of objective subgroup 3 was specifically dealing with (probably it 
overlaps with SG1 objectives) [1]. We however performed the grading, that was very 
low. 
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Observational	study 1 Very	low	evidence		-	Downgraded	study
Year 2008
Journal BJN
First	Author Tseng
Statistical	method Logistic	regression
Inclusion	criteria SAH
Treatment Synthetic	colloids
Outcome
unfavourable	6-month	GOS	(1-3):	52	(32.5%)
Centres 1 Variable:	OR	(95%-CI)
N°	patients/centre/year NA Colloids	L/day:	2.53	(1.13-5.68)
Study	duration	(days) 820 Crystalloids	L/day:	0.27	(0.11-0.67)
Total	(included	in	the	
model)
160
GRADE	CRITERIA
Statistical	reporting	 Partial
Statistical	quality Low
Appropriate	eligibility	criteria Yes
Measurement	of	exposure Yes
Measurement	of	outcome Yes
	Adequate	control	for	
confounding
No
Bias very	serious
GRADE		overall
Size	of	effect Large
Residual	confounding Does	not	indicate	upgrading
Dose	/response Not	applicable
DETAILS
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p
-
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External	validity
GRADE	rating	up/down Downgraded	study
GRADE	rating Very	low	evidence
Statistical	reporting	 Partial
Statistical	quality Low
External	validity	issues Yes
Final	grading Downgraded	study
Final	level	of	evidence Very	low	evidence
Conclusive	evaluation	
U
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-
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g
Size	of	effect:	We	did	not	upgrade	for	the	large	effect	because	it	was	the	result	of	a	biased	model.	
Statistical	reporting	:	The	reporting	of	multivariable	results	is	insufficient	to	uderstand	how	the	model	was	
developed	in	detail.	Statistical	quality:	Variables	were	selected	with	an	automatic	procedure	which	does	not	
grant	the	development	of	a	reasonable	model	especially	when	the	sample	size	is	small.	No	propensity	score	was	
developed	although	the	research	was	dealing	with	a	treatment.	The	number	of	variables	were	probably	too	few	
to	predict	a	complex	outcome.	
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SG3 Q4 Can brain multimodal neuromonitoring parameters (CBF, PbtO2, TCD) 
be used as trigger or endpoint to guide fluid therapy in the management of 
cerebral ischemia? 
 
Studies were too heterogeneous to be combined in an overall body of evidence. Their 
individual grading (reported in the quality assessment forms at the end of this 
document) hence corresponds to the body of evidence grading. 
 
 
Two studies investigated fluid administration effect on brain tissue oxygen partial 
pressure. When a fluid bolus with 250 ml of albumin determined an increase of the 
cardiac index an improvement in tissue oxygenation was measured [1]. Although the 
study used a multivariable approach that accounted for multiple measurements, it 
was carried out on ten patients only raising both internal and external validity issues. 
The study evidence was, hence, rated very low. The second study was carried out on 
patients with vasospasm following subarachnoid haemorrhage. It concluded that 
hypervolemia combined with hypertension determined tissue oxygenation 
improvement but frequent adverse effects. We could not evaluate clearly the effect 
of hypervolemia alone because of the study design. Evidence was considered very low, 
in this case also. 
Several studies used micro-dialysis to measure extracellular glucose, lactate, 
lactate/pyruvate ratio, glutamate, and glycerol in patients with subarachnoid 
hemorrhage to detect ischemia [2-7]. These studies, however, did not test the 
effectiveness of fluid therapy in reversing ischemia. Thus, for the purpose of our 
review they do not provide useful evidence. 
Another study with the same limitations was focused on the comparison of 
transcranial Doppler and cerebral arterial-venous oxygen differences [8].
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SG3 Q5 Should a change in neurological status trigger a change in fluid 
management away from euvolemia in stroke patients with cerebral ischemia? 
 
Studies were too heterogeneous to be combined in an overall body of evidence. Their 
individual grading (reported in the quality assessment forms at the end of this 
document) hence corresponds to the body of evidence grading.  
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Two studies treated new neurological symptoms in SAH with hypervolemia using 
albumin, glicerol, dextran, or plasma, monitoring part of these patients with a Swan-
Ganz catheter. Neurologic improvement and absence of progression to infarction in 
most cases led the authors to conclude that hypervolemic therapy was effective [1, 
2]. The two studies, however, had very serious limitations connected to the small 
sample size, to the absence of a instrumental diagnosis of vasospasm, no specific 
definition of teatment, and lack of adjustment for confounding factor. 
Both GRADE and our final evaluations rated evidence provided by both studies as very 
low. 
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SG3 Q6 Should early goal directed fluid therapy (GEDI) have a place in the 
management of DCI? 
 
SG1 Q5 Is there evidence to support the use of hemodynamic monitoring or 
echocardiography to guide the fluid management in the resuscitation of acute brain 
injury (TBI, SAH, ICH, severe MCA stroke)? 
 
 
The answer to Q6 also provided the answer to SG1 Q5. 
Only one RCT and three observational studies received a detailed reporting of grading. 
The RCT was focused on the maintenance of a high global end-diastolic volume index 
(GEDI) measured using invasive cardiac monitoring compared to standard treatment 
[1]. The trial was negative in terms of DCI and 3 moths poor outcome frequency. A 
predefined analysis on patients with poor grade subarachnoid hemorrhage that were 
stratified at randomization, showed a statistically significant reduction of both 
outcomes. However, according to our calculation neither results was statistically 
significant (p = 0.10 for DCI and p = 0.07 for 3-month poor outcome) using the same 
statistical tests as the authors. Either way, the latter was a subgroup analysis and thus 
could only generate hypothesis and not provide definitive conclusions.  We graded 
evidence provided by the study as moderate but raising doubts on the reliability of the 
statistical significance of the study. 
The observational studies were methodologically biased and provided very low quality 
evidence [2-4]. 
We only mention, without reporting in detail our grading process, other observational 
studies heterogeneous in design and methodologically poor providing evidence [5-9].  
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RCT	1
Year 2014 First	Author Mutoh
Journal Stroke
Sample Poor	grade	SAH	(subgroup	analysis)
Treatment GEDI	≥	680	ml/m2
Control Standard	treatment
Outcome DCI
n°	pz n %
Treatment 80 4 5.0
Control 80 11 13.8
Total 160 15 9.4
Centres Single	Center
Power 0.484
GRADE	CRITERIA
Allocation	concealment No
Intention	to	treat	principle	observed Yes
Blinding No
Completement	of	follow-up Yes
Early	stopping No
Bias No
Statistical	reporting	
Sufficient	for	quality	
assessment
Indirectness No
Imprecision serious
Publication	bias Not	assessable
Inconsistency	with	other	trials No
Size	of	effect Large
Residual	confounding Not	assessable
Dose	/response Not	relevant
DETAILS
GRADE	rating Moderate	evidence
Statistical	reporting	
Sufficient	for	quality	
assessment
Methodological	and	statistical	quality High
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Moderate	evidence
Methodological	and	statistical	quality:	A	stratified	
randomization	was	wisely	performed	onthe	basis	of	WFNS	I-III	
and	IV-V.	Outcome	assessment	was	performed	by	a	blinded	
investigator.	The	sample	size	was	based	on	a	very	large	
reduction	of	DCI	incidence	(25%)	assuming	a	very	high	
incidence	in	the	control	group	(40%),	that	were	not	supported	
by	literature	data;	
U
p
-g
ra
d
in
g Size	of	effect	Large:	The	large	relative	risk	reduction	(64%)	was	
barely	not	statistically	significant,	but	confidence	intervals	
were	large	and	methodology	was	not	sufficiently	robust.	
There	was	no	indication	for	upgrading.	
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Outcome
NNTB	11	(95%-CI	NNTB	5	to	∞	to	NNTH	190)
delta	-8.8	(95%-CI	-18.5	to	0.5)
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RCT	2
Year 2014 First	Author Mutoh
Journal Stroke
Sample Poor	grade	SAH	(subgroup	analysis)
Treatment GEDI	≥	680	ml/m2
Control Standard	treatment
Outcome 3-months	mRS	4-6	
n°	pz n %
Treatment 80 53 66.3
Control 80 64 80.0
Total 160 117 73.1
Centres Single	Center
Power 0.510
GRADE	CRITERIA
Allocation	concealment No
Intention	to	treat	principle	observed Yes
Blinding No
Completement	of	follow-up Yes
Early	stopping No
Bias serious
Statistical	reporting	
Sufficient	for	quality	
assessment
Methodological	and	statistical	quality High
Indirectness No
Publication	bias No
Inconsistency	with	other	trials No
Size	of	effect Not	relevant
Residual	confounding Not	assessable
Dose	/response Not	relevant
DETAILS
GRADE	rating Moderate	evidence
Statistical	reporting	
Sufficient	for	quality	
assessment
Methodological	and	statistical	quality High
External	validity	issues Yes
Final	grading Downgrading
Final	level	of	evidence Moderate	evidence
Bias:	A	stratified	randomization	was	wisely	performed	onthe	
basis	of	WFNS	I-III	and	IV-V.	Outcome	assessment	was	
performed	by	a	blinded	investigator.	The	sample	size	was	
based	on	a	very	large	reduction	of	DCI	incidence	(25%)	
assuming	a	very	high	incidence	in	the	control	group	(40%),	
that	were	not	supported	by	literature	data;	Publication	bias:	
The	large	relative	risk	reduction	(64%)	was	barely	not	
statistically	significant,	but	confidence	intervals	were	large	and	
methodology	was	not	sufficiently	robust.	There	was	no	
indication	for	upgrading;	
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Outcome
NNTB	7	(95%-CI	NNTB	4	to	∞	to	NNTH	8762)
delta	-13.8	(95%-CI	-26.9	to	0)
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Observational	study 1 Very	low	evidence		-	Downgraded	study
Year 2014
Journal CC
First	Author Mutoh
Statistical	method Logistic	regression
Inclusion	criteria SAH	in	Takotsubo	cardiomyopathy
Risk	factor Cardiac	Function	Index	(CFI)	<	4.2/min
Outcome
#VALUE!
Centres 1 Variable:	OR	(95%-CI)
N°	patients/centre/year NA CFI	<	4.2	duration	(days):	2.14	(1.33-2.84)
Study	duration	(days) 2921
Total	(included	in	the	
model)
46
GRADE	CRITERIA
Statistical	reporting	 Partial
Statistical	quality Low
Appropriate	eligibility	criteria Yes
Measurement	of	exposure Yes
Measurement	of	outcome Yes
	Adequate	control	for	
confounding
No
Bias very	serious
GRADE		overall
Size	of	effect Large
Residual	confounding Does	not	indicate	upgrading
Dose	/response Not	applicable
DETAILS
D
o
w
n
gr
ad
in
g
U
p
-
gr
ad
in
g
External	validity
GRADE	rating	up/down Downgraded	study
GRADE	rating Very	low	evidence
Statistical	reporting	 Partial
Statistical	quality Low
External	validity	issues Yes
Final	grading Downgraded	study
Final	level	of	evidence Very	low	evidence
Conclusive	evaluation	
Single	center	study
U
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Size	of	effect:	We	did	not	upgrade	for	the	large	effect	because	it	was	the	result	of	a	biased	model.	
Statistical	reporting	:	The	reporting	of	multivariable	results	is	insufficient	to	uderstand	how	the	model	was	
developed	in	detail.	Statistical	quality:	Bivariate	analysis	was	used	for	variables	selection	using	0.05	cut-off	for	p	
value,	which	generates	a	high	risk	of	exluding	important	predictors.	It	was	followed	by	an	automatic	procedure	
which	does	not	grant	the	development	of	a	reasonable	model.	Finally,	logistic	regression	is	not	the	best	
statistical	tool	for	managing	time-dependent	variables.	With	only	46	patients	included	in	the	model	(the	number	
of	outcomes	were	not	specified)	and	three	variables	included	the	model	was	surely	overfitted.	On	the	other	
hand	the	only	three	variables	generate	an	underfitted	model	for	its	explanatory	purposes.	
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Observational	study 2 Very	low	evidence		-	Downgraded	study
Year 2014
Journal CCM
First	Author Tagami
Statistical	method Cox	proportional	hazards
Inclusion	criteria
Risk	factor Mean	GEDI	(ml/m2)
Outcome
1-year	mortality:	35	(19.4%)
Centres 9 Variable:	OR	(95%-CI)
N°	patients/centre/year 6 Mean	GEDI	(100	units	variation):	0.72	(0.58-0.91)
Study	duration	(days) 1277
Total	(included	in	the	
model)
180
GRADE	CRITERIA
Statistical	reporting Partial
Statistical	quality Low
Appropriate	eligibility	criteria Yes
Measurement	of	exposure Yes
Measurement	of	outcome Yes
	Adequate	control	for	
confounding
No
Bias serious
GRADE		overall
Size	of	effect Not	relevant
Residual	confounding Does	not	indicate	upgrading
Dose	/response Not	applicable
DETAILS
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ad
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g
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-
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ad
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g
External	validity
GRADE	rating	up/down Downgraded	study
GRADE	rating Very	low	evidence
Statistical	reporting Partial
Statistical	quality Low
External	validity	issues No
Final	grading Downgraded	study
Final	level	of	evidence Very	low	evidence
Conclusive	evaluation	
D
o
w
n
gr
ad
in
g
No	external	validity	issues
SAH
U
p
-
gr
ad
in
g
Measurement	of	outcome:	A	combined	outcome	including	severe	disability	besides	mortality	is	to	be	preferred	to	
mortality	alone	when	dealing	with	long-term	neurologic	outcome.	Statistical	quality:	With	only	35	patients	
developing	DCI	and	at	least	eight	variables	included	the	model	was	surely	overfitted.	On	the	other	hand		only	3-4	
variables	that	could	have	been	included	in	the	model	to	avoid	overfitting	would	have	generated	an	underfitted	
model	for	its	explanatory	purposes.	
 
OBSERVATIONAL 
 
 
Group 3 
 
 
Observational 3 Very	low	evidence		-	No	grading	modification
Year 2013
Journal Stroke
First	Author Yoneda
Statistical	method Logistic	regression	with	propensity	score	adjustment
Inclusion	criteria
Risk	factor Mean	GEDI	(ml/m2)
Outcome
DCI:	52	(25.5%)
Centres 9 Variable:	OR	(95%-CI)
N°	patients/centre/year 6 Mean	GEDI	(per	unit	variation):	0.997	(0.995-1.0)
Study	duration	(days) 1278
Total	(included	in	the	
model)
204
GRADE	CRITERIA
Statistical	reporting Sufficient	for	quality	assessment
Statistical	quality Low
Appropriate	eligibility	criteria Yes
Measurement	of	exposure Yes
Measurement	of	outcome Yes
	Adequate	control	for	
confounding
No
Bias No
GRADE		overall
Size	of	effect Not	relevant
Residual	confounding Does	not	indicate	upgrading
Dose	/response Not	applicable
DETAILS
D
o
w
n
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ad
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External	validity
GRADE	rating	up/down No	grading	modification
GRADE	rating Very	low	evidence
Statistical	reporting Sufficient	for	quality	assessment
Statistical	quality Low
External	validity	issues No
Final	grading No	grading	modification
Final	level	of	evidence Very	low	evidence
Conclusive	evaluation	
D
o
w
n
gr
ad
in
g
No	external	validity	issues
U
p
-
gr
ad
in
g
SAH	patients
Statistical	quality:	Insufficient	information	on	how	the	model	was	developed	(e.g.	variable	selection,	
management	of	continuous	variables)	and	on	the	vresults	of	the	modewere	provided.	We	suppose	that	the	risk	
of	underfitting	on	one	hand	and	overfitting	on	the	other,	have	limited	the	reliability	of	the	analyses.	
